

EVER 2009



## European Association for Vision and Eye Research

September 30 - October 3, 2009  
Portoroz, Slovenia



[www.ever.be](http://www.ever.be)


*Concordia Visu*

21 CME credits



The image consists of a repeating, diagonal grid pattern of text. The primary text element is 'PROGRAMME BOOK', which is repeated numerous times in a light blue color. This text is arranged in rows that slope upwards from left to right. Interspersed among these are the letters 'PROC', also in light blue, which appear less frequently but follow a similar diagonal arrangement. The overall effect is a textured, watermark-like background.

## Word from the President



Charles RIVA  
EVER President 2009

Dear Colleagues and Friends,

It gives me a great pleasure to welcome you to the 12th annual meeting of the European Association for Vision and Eye Research.

In keeping with the tradition of EVER, we have been able, thanks to your contributions, to put together under the guidance of the Programme Secretary a well balanced scientific programme in the form of special interest symposia, plenary lectures, courses and free papers. This programme continues to show a healthy mixture of high standard clinical and basic science and wide participation from the ophthalmic and vision science communities at large. We believe that it will provide an environment that will promote the interaction between clinicians and researchers and lead to new ideas and research directions. Further stimulating international collaborations and extending EVER international reputation are the scientific sessions put together by a number of major eye organizations, as well as this year's joint meeting of KPro study group in collaboration with EVER.

This scientific programme will be accompanied by social events and you are all invited to the Welcome Reception on the evening of the 30th of September. I hope you will also join us at the EVER Farewell Dinner and Musical Entertainment.

The meeting concludes EVER's triple visit to charming Portoroz. We are extremely grateful to our Slovenian colleagues under the steering of Marko Hawlina for securing an excellent venue and their valuable work in providing support for successful conferences.

This conference would not be possible without our sponsors, whose generosity in these difficult global economic times deserves our gratitude and appreciation.

I am looking forward to meeting you in Portoroz and all my thanks to all who have worked hard for the success of this meeting.

Yours sincerely

Charles RIVA  
EVER President 2009

# About EVER

EVER is a non-profit organisation. The aims of the association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is the largest European scientific organization which covers all subspecialties of ophthalmology and visual sciences. It provides an umbrella for other ophthalmological societies to meet during its annual congress. The official journal of EVER is Acta Ophthalmologica.

## Membership

Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the member's module, on [www.ever.be](http://www.ever.be) and fill in the name of an EVER member who will endorse their application. If candidates do not know a member who can endorse their application, they should write to the EVER office, which will take appropriate action. The candidate becomes a member upon recommendation by the EVER board and upon payment of the dues.

### As an EVER member your benefits are:

- reduced fee for the annual meeting
- possibility of organizing Special Interest Symposia (SIS) during the annual meeting
- voting rights for the election of the Board Members
- free electronic subscription to Acta Ophthalmologica, the EVER journal
- travel grants for best paper in each section
- quarterly E-Newsletter

## Elections

This year new representatives of the scientific sections Anatomy/Cell Biology, Molecular Biology / Genetics / Epidemiology and Vision Sciences / Electrophysiology / Physiological optics, will be elected through electronic voting. Voting 2009 will close on October 2, midnight. The result of the elections will be announced at the General Assembly on Saturday October 3, 2009. The scientific sections will hold their Business Meetings on Friday, October 2, 2009 from 12:35 - 13:35. Sandwiches and refreshments are provided. The agenda is available on page 41.

The following 2 sections will nominate at least 2 candidates for the succession of their representatives in the Board of EVER for elections in 2010: Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History of Ophthalmology and Pathology/Oncology.

The statutes and by-laws are available on the website: [www.ever.be](http://www.ever.be) » about » statutes



Programme Committee 2009

## Section secretaries

ACB	= Anatomy/Cell Biology	Erich KNOP
COS	= Cornea/Ocular Surface	Jean-Jacques GICQUEL
G	= Glaucoma	Ingeborg STALMANS
IM	= Immunology/Microbiology	Carl HERBORT
LC	= Lens and Cataract	Jan-Olof KARLSSON
MBGE	= Molecular Biology/Genetics/ Epidemiology	Marzena GAJECKA
NSPH	= Neuro-ophthalm./Strabism./ Paediatric Ophthalm/ History of Ophthalm.	Aki KAWASAKI
PBP	= Physiology/Biochemistry/Pharmacology	Neville OSBORNE
PO	= Pathology/Oncology	Steffen HEEGAARD
RV	= Retina/Vitreous	Elisabeth VAN AKEN
VEP	= Vision Sciences/Electrophysiolog./ Physiological Optics	Werner SPILEERS
<b>Programme secretary</b>		<b>Tero KIVELÄ</b>

# Board members 2009

## Executive Committee



Charles Riva  
President



Bahram Bodaghi  
Secretary General



Pinar Aydin  
Treasurer



Tero Kivelä  
Programme Secretary



Graham Holder  
President Elect



Ralph Michael  
Vice-President



Marcela Votruba  
Vice-President Elect



Erich Knop  
Vice-President Elect



Harminder Dua  
Past President

## Section chairs



Erich Knop  
ACB



Philippe Kestelyn  
COS



Thiery Zeyen  
G



Carl Herbort  
IM



Alfred Wegener  
LC



Marcela Votruba  
MBGE



Lene Martin  
NSPH



Charlotta All-Ericsson  
PO



Leopold Schmetterer  
PBP



Constantin Pournaras  
RV



Graham Holder  
VEP

## Regional representatives



Francesco Bandello  
Italy



Rimvydas Asoklis  
East Europe



Pinar Aydin  
Greece, Balkan, Middle-East



Marko Hawlena  
Slovenia

## Local representative

## Co-opted



Martine Jager  
Advocacy



Amanda Churchill  
Advisor

## EVER office



Kapucijnenvoer 33  
3000 Leuven, Belgium  
marlene.verlaeckt@ever.be  
www.ever.be

# General information

## Venue

EVER 2009 will be held at the Bernardin Convention Center in Portoroz, Slovenia (visit the website on [www.h-bernardin.si/en/congress\\_centre](http://www.h-bernardin.si/en/congress_centre)).

The scientific programme of the EVER congress starts on Wednesday, September 30 at 12:00 and concludes on Saturday, October 3 at 19:15.

## Registration

Everyone attending the scientific sessions - whether or not an EVER member, invited speaker, accompanying person or presenter - must register and pay the registration fee.

The early registration deadline is September 1, 2009. On-site registration will be open from Wednesday, September 30, 11:00.

### Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- registering as an accompanying person entitles you to attend the EVER social events, but not the scientific programme

## Cancellation policy

Refunds – up to 75% of the advance registration fee will be granted for cancellation received in writing prior to September 20, 2009. Refunds will not be granted for later cancellations or no-shows.

## Registration fees after Sept. 1, 2009

	EUR	EUR
EVER member	350	275 *
SIS-invited speaker	350	275 *
Member-in-training	175	140 *
Non-member	570	460 *
Non-member-in-training	280	220 *
Course	50	30 *
Accompanying person	115	115 *

\* Citizens of these listed countries only: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Congo, Croatia, Czech Republic, Egypt, Estonia, Georgia, Hungary, India, North Korea, Latvia, Libya, Lithuania, Macedonia, Moldova, Montenegro, Morocco, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Tunisia, Turkey, Ukraine. The list of countries will be updated annually and is based on the membership roster.

## Website

The EVER website [www.ever.be](http://www.ever.be) has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2009 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- go to useful links, such as Concordia visu
- express your vote for officers
- print your CME certificate after the congress



EVER is on Twitter. Stay up to date and follow EVER at EVERforever.

## Travel

Portoroz can be reached from Trieste airport (Italy) and from Ljubljana airport (Slovenia).

A congress shuttle service is available. Please book in advance through [www.ever.be](http://www.ever.be) » housing and transfer.

- Congress transfer service\* from Ljubljana and Trieste airport to Portoroz:  
- on arrival dates September 29-30.  
- on departure dates October 3-4.
- One-way shuttle bus transfer:  
Ljubljana airport to Portoroz: 35 EUR/person (90min.)  
Trieste airport to Portoroz: 30 EUR/person (90min.).
- Private transfer: individual service, private car or van transfer with English-speaking driver can be organised. Please contact: [housing@cd-cc.si](mailto:housing@cd-cc.si).

\* Arrivals: The congress transfer service reserves the right to combine transfers for participants of the EVER congress with a maximum waiting time of 1 hour.

Departures: Please reconfirm your departure transfer at least 48 hrs prior to your departure at the housing desk.

## Tourist information

Slovenia is a country where the Alps meet the sea, a country of geographical diversity and natural beauty that you will be able to observe already on the way from Ljubljana airport to the town of Portoroz. Portoroz and Piran are two towns next to each other. The old tradition of Piran is matched with modern amenities in hotels that offer relaxing atmosphere and splendour.

The congress center is situated right in the middle of the two. The towns have many places offering pleasant atmosphere, with seafood restaurants and delicious wines.

## Weather

September - October is an excellent time to visit Slovenia. It is the latter part of the warmest and driest time of the year.

## Guidelines for speakers Handling presentations at EVER 2009

EVER 2009 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:

The supported software used for the presentations is PowerPoint.

### **Include your conflict of interest statement in the first slide.**

Oral presentations in the free paper sessions are limited to eight minutes, followed by four minutes of discussion. The session chairman will strictly enforce this schedule.

Rapid fire presentations should last no longer than 3-4 minutes with a 2 further minutes for questions from the audience. Do not use more than 2-3 PowerPoint slides for this presentation.

In the Speaker's room Mediteranea II, a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied.

Inside each presentation hall, a technical assistant starts each presentation at the right time using one of the fixed computers connected to the central congress network.

We do not allow the use of personal laptops for presentations except in rare circumstances (for example, when the presentation has been created with movie creating software). If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed.

Of course, the easiest way is to bring your presentation on CD, DVD or memory stick. E-mailing or uploading of presentations will not be encouraged but can be used in special circumstances.

When a speaker wants to modify the presentation after it has been transferred to the central congress network, it can of course be updated to the new version upon request.

Centrally stored data will be deleted at the end of the congress so no copyright issues will arise.

## Best oral presentation prize

A prize of 100 EUR will be awarded for the best oral presentation in each free paper session. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday October 3.

## Guidelines for posters

The poster exhibition takes place in Hall Europa C. Posters must be brought to the congress by the presenting author and should not be mailed in advance. The required dimensions are 95 cm (wide) by 180 cm (high). NOTE: **Portrait shape. Include your conflict of interest statement in your poster.**

Each poster is exhibited for one day only. All posters should be erected between 08:00 and 09:00 hrs on the day of presentation and must not be removed until 19:00 hrs. EVER is not responsible for any poster left behind at the end of the day.

You will find the number of your posterboard in one of the poster sessions of this programme book.

You are required to stand beside your poster during the poster session. On Thursday and Friday from 16:15 to 17:25, on Saturday from 15:20 - 16:30. During this time, moderators will be voting which poster should win the poster prize.

Some authors of posters, selected by the programme committee will be invited to give a brief rapid fire oral presentation.

## Poster prizes

A poster prize of 200 EUR will be awarded for the best poster in each section. An additional VEP poster prize will be generously sponsored by the Alta Eficacia Tecnología, SL, Spain. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday October 3.

## Withdrawals

First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2009.

## No shows

Please note that any first author, whose paper or poster, once it has been accepted, is not presented without a valid excuse, will be prohibited from presenting papers at EVER for the next two years.

## Liability

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.

## Social programme

The social programme is open for all participants and registered accompanying persons:

- Wednesday 19:00, EVER Opening concert and welcome reception
- Saturday 20:00, EVER Farewell dinner

## Coffee

Included in the registration fee are the coffee and soft drinks throughout the meeting from 09:45 until 11:00 and from 15:30 until 17:25 and the sandwiches and refreshments at the time of section business meetings on Friday 12:35-13:35.

## Internet access

Wi-Fi internet access will be provided in Foyer next to hall Europa A. Please note the new location.

## Photographs

 It is strictly forbidden to take photographs or videos of the presentations in the lecture Halls.

## Publication of the abstracts

The abstracts of the EVER 2009 congress will be published on-line in a special issue of Acta Ophthalmologica:


[http://www3.interscience.wiley.com/  
journal/119816726/group/home.html](http://www3.interscience.wiley.com/journal/119816726/group/home.html)

## Business meetings


- **EVI General Assembly**  
Thursday, 14:00 in Hall Aurora
- **EVER BUSINESS MEETINGS OF THE SCIENTIFIC SECTIONS**  
Friday, 12:35 - 13:35
 

Europa A	RV
Europa B	VEP/PBP
Emerald I	COS/ACB
Emerald II	LC/MBGE
Mediterranea I	G/IM
Adria	PO/NSHP
- **EVER GENERAL ASSEMBLY**  
Saturday, 16:40 in Hall Europa A
- **OOG, Ophthalmic Oncology Group**  
Saturday, 17:45 - 19:15, in Hall Adria


## Ground floor




## 11<sup>th</sup> floor



## 12<sup>th</sup> floor





## EVER travel grants

We are pleased to announce that the following 11 members have received a travel grant of 400 EUR each from the EVER Sections:

- ACB  
**Goran PETROVSKI** - Hungary  
Clearance of dying cells in the retina-relevance to age-related macular degeneration
- COS  
**Maria DE LA PAZ** - Spain  
Ocular surface findings in patients with congenital aniridia
- G  
**Amit TODANI** - USA  
Measurement of IOP with radiowave telemetry
- IM  
**Eva JAKOB** - Germany  
Three years experience of Quantiferon® Gold testing
- LC  
**Marcus KERNT** - Germany  
Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell-death by reducing oxidative stress and stabilizing BAX/Bcl-2 ratio
- MBGE  
**Tine VAN BERGEN** - Belgium  
Is inhibition of VEGF165 sufficient to inhibit scar formation after trabeculectomy?
- NSPH  
**Raffaella ANGELI** - Italy  
Preterm and at term children: morphological and functional analysis of optic nerve and visual pathway with OCT, HRT and pVEP
- PO  
**Justyna DOPIERALA** - UK  
Heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification (MLPA)
- PBP  
**Johanna VIIRI** - Finland  
Cis-urocanic acid suppresses UV-B-induced interleukin-6 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro
- RV  
**Estratios MENDRINOS** - Switzerland  
Internal limiting membrane surrounding idiopathic stage 4 macular hole contains bundles of actin microfilaments
- VEP  
**Torsten STRASSER** - Germany  
Development of a software for the exchange of electrophysiological data of vision with PACS systems based on DICOM

## EVER listed countries travel grants

We are pleased to announce that the following 10 members from listed countries will receive a travel grant for the amount of 400 EUR:

- Russia - **Andrey KACHANOV**  
LASIK surgery for myopia in Chinese patients
- Serbia - **Svetlana STANOJLOVIC**  
Immune regulatory effect of rapamycin and cyclosporine A on experimental corneal allograft survival
- Hungary - **Anita GARAS**  
RTVue Fourier-domain OCT: reproducibility of RN-FLT and macular thickness measurements
- Czech Republic - **Vladimir HOLAN**  
Treatment of ocular surface injuries by the transfer of limbal and mesenchymal stem cells growing on nanofibrous scaffolds
- Slovenia - **Spela STUNF**  
Ultrastructure of anterior lens capsule in uveitic cataract
- Poland - **Marzena GAJECKA**  
Gene screening at the 13q32 keratoconus locus
- India - **Sumita SETHI**  
A Western blot analysis of P-glycoprotein in retinoblastoma
- Latvia - **Liga RADECKA**  
Wet AMD treatment with ranibizumab - structural and functional changes during treatment
- Slovenia - **Natasa VIDOVIC**  
The role of VEGF in intermediate uveitis patients
- Lithuania - **Loresa KRIAUCIUNIENE**  
Optico-anatomical changes of premature children eyes

## TFOS grants



TFOS is pleased to announce that the following three researchers have received a travel award from the Tear Film and Ocular Surface Society for the three best abstracts submitted to EVER 2009 by young researchers in the cornea section:

- **Jared AMENT**: Boston, USA
- **Stefano BARABINO**: Genoa, Italy
- **Antonia DEMESTICHA**: Heraklion, Greece

## Alta Eficacia Tecnología SL, Spain, travel grant

Alta Eficacia Tecnología is pleased to announce a travel grant of 400 EUR for the best paper in the VEP section

- **Franziska RAUSCHER** - UK  
Differential effects of ageing on foveal and peripheral colour vision



**Wednesday  
September 30, 2009**



## WEDNESDAY

<b>Europa A</b>	<b>IM: Immune modulation in ocular disease: practice and controversies</b>	12:00 – 14:15
<b>Course 1</b>	Uwe PLEYER, Carl P HERBORT, Bahram BODAGHI, Piergiorgio NERI	<span style="background-color: #e67e22; color: white; border-radius: 50%; padding: 5px 10px; display: inline-block;">NEW</span> <span style="background-color: #2ecc71; color: white; border-radius: 50%; padding: 5px 10px; display: inline-block;">Intermediate</span>
<p>The course presents an update on current practice of inflammation suppressive therapy indicate the indications, advantages and drawbacks of the different treatment modalities at our disposal including corticosteroids, immunomodulators, immunosuppressants and biological agents. In addition it addresses the (new) modalities at our disposal to optimally monitor the impact of inflammation suppressive therapy.</p>		
12:00	Introduction by Uwe Pleyer	
12:03	1211 Prevention of corneal graft rejection PLEYER U-Berlin	
12:13	1212 Principles of immunosuppression in uveitis WILLERMAIN F, CASPERS L-Bruxelles	
12:25	1213 The present role of corticosteroids in uveitis KHAIRALLAH M-Monastir	
12:35	1214 Traditional immunosuppressants for uveitis DE SMET M-Lauzanne	
12:50	1215 Interferon-alpha for uveitis BODAGHI B, DICK AD-Paris, Bristol	
13:00	1216 Immunosuppression in children (JIA) BODAGHI B-Paris	
13:10	1217 Infliximab (Remicade®) in uveitis: a review ABU EL ASRAR A, NERI P, HERBORT CP-Riyadh, Torrette-Ancona, Lausanne	
13:20	1218 Final results of European Remicade® RESCU study DE SMET M-Lauzanne	
13:30	<b>Break</b>	
13:35	1219 Adalimumab (Humira®) therapy for uveitis NERI P-Ancona	
13:45	121a Mycophenolate mofetil in uveitis NERI P-Ancona	
13:55	121b Optimised monitoring of inflammation suppressive therapy (IST) in uveitis HERBORT CP-Lausanne	
14:07	121c The future in immunomodulation DE SMET M-Lauzanne	

<b>Emerald I</b>	<b>PO: Well versed in statistics - Basics and writing skills</b>	12:00 – 14:15
<b>Course 3</b>	Tero KIVELÄ, Bertil DAMATO	<span style="background-color: #2ecc71; color: white; border-radius: 50%; padding: 5px 10px; display: inline-block;">Beginner</span>
<p>Typical pitfalls, seldom addressed during basic courses in statistics, await the unwary scientist who is starting research in ophthalmology. These include proper ways of analysing data collected from both eyes of patients and proper ways of summarising and comparing visual acuities. Moreover, more senior scientists who regularly review manuscripts are aware of certain problems in presentation of data that should be trivial to solve, but which are surprisingly persistent. These comprise handling of follow-up data, recognising the often neglected yet common problem of multiple comparisons, how to communicate effect size, and how to cope with statistically non-significant results. This course will clarify the problems mentioned, based on examples from real life and from a practical rather than mathematical point of view. It will additionally provide guidelines for clear presentation of key aspects of research. After this course, your paper and statistics should be more likely to successfully pass the review process, and you should be in a better position as a reader and reviewer as well.</p>		
12:00	1231 Pitfalls in statistics and how to avoid them - part 1 KIVELÄ T-Helsinki	
12:35	<b>Break</b>	
12:50	1232 Tips and tricks for writing a manuscript DAMATO B-Liverpool	
13:25	<b>Break</b>	
13:40	1233 Pitfalls in statistics and how to avoid them - part 2 KIVELÄ T-Helsinki	

Mediterranea I	<b>RV: EBO Review Course: From clinical analysis to final diagnosis: semiology is the key</b>	12:00 – 14:15
Course 4	Catherine CREUZOT	
<b>NEW</b> <b>Beginner</b>		
<p>This course dedicated to residents for EBO training will highlight the interest of semiology in the analysis of clinical cases from various origins. Authors will focus their talk on the key role played by fundus analysis and the need of a good physiology and anatomy knowledge to understand the symptoms. The aim of this course is not to reach the diagnosis but rather to describe and to analyze the different items that are provided, ranging from visual field, angiogram, OCT, ERG, EOG, videotopography, aberrometry.</p> 		
12:00	1251	Diabetic retinopathy POURNARAS CJ, MENDRINOS E–Geneva
12:20	1252	Pigmented lesions DESJARDINS L–Paris
12:40	1253	Age related macular degeneration VOIGT M–Paris
13:00		<b>Break</b>
13:15	1254	Retinal dystrophies HAWLINA M–Ljubljana
13:35	1255	What do I need to improve my glaucoma skills? BRON AM–Dijon
13:55	1256	Refraction and refractive surgery COCHENER B–Brest

Europa B	<b>COS: Corneal Infectious disease</b>	14:30 – 16:45
Course 5	Jean-Jacques GICQUEL, Harminder S DUA	
<b>Intermediate</b>		
<p>14:30 1321 Corneal bacterial infections CREUZOT C, BRON AM, BOURCIER T–Dijon, Strasbourg</p>		
14:50	1322	Infectious crystalline keratopathy DUA HS–Nottingham
15:10	1323	Epidemiology of viral infections LABETOULLE M–Kremlin-Bicetre
15:30		<b>Break</b>
15:45	1324	Herpes and zoster keratitis BOURCIER T–Strasbourg
16:05	1325	Fungal infections KESTELYN P–Gent
16:25	1326	Parasitic corneal infections GICQUEL JJ–Poitiers

<b>Emerald II RV: Retinal detachment</b>	14:30 – 16:45
<b>Course 6</b> Catherine CREUZOT, Constantin POURNARAS	
<b>NEW</b> <b>Intermediate</b>	
<p>This course is dedicated to retinal detachment. Authors will consider successively the consequence of retinal detachment (RD) on retina with the results obtained from experimental models of RD. Then clinical cases of rhegmatogenous RD will be discussed with the various therapeutic options in pseudophakic and aphakic patients and particularly the indication of scleral buckling during primary vitrectomy. Some complicated cases occurring during uveitis or after ocular trauma will be presented. Finally the management of glaucoma after retinal surgery will be considered.</p>	
14:30	1341 What is the consequence of retinal detachment on anatomy and function? CREUZOT C-Dijon
14:50	1342 Retinal detachment in phakic patients CHIQUET C-Grenoble
15:10	1343 Primary vitrectomy in retinal detachment: is scleral buckling still indicated? POURNARAS CJ-Geneva
15:30	<b>Break</b>
15:45	1344 Retinal detachment after ocular trauma JONAS JB-Mannheim
16:05	1345 Retinal detachment after uveitis DE SMET M-Lauzanne
16:25	1346 Glaucoma and retina BRON AM-Dijon

<b>Adria PO: EBO Review Course: Ophthalmic Oncology</b>	14:30 – 16:45
<b>Course 7</b> Laurence DESJARDINS	
<b>Intermediate</b>	
<p>Objectives: at the conclusion of this course the attendee will be able to list the main ophthalmic malignant tumours, their symptoms and usual diagnostic tools.</p>	
<p>This course will focus on ocular, conjunctival, lid and orbital tumours. The first lecture will give an overview of the different intraocular and adnexal tumours with the clinical presentation and symptoms, pathology and main diagnostic tools. Clinical presentation, diagnosis and management of uveal melanoma will be covered as well as clinical presentation, diagnosis and treatment of retinoblastoma. The main conjunctival, lid and orbital tumours and their usual management will be described. Clinical cases will be presented as well as multiple choice questions. The goal of the course is to give the attendee some knowledge about the most frequent ophthalmic tumours with their clinical presentation and differential diagnosis with the ancillary tests and imaging tests to be performed for each of them.</p>	
14:30	1361 Diagnosis of ophthalmic tumours KIVELÄ T-Helsinki
14:45	1362 Management of uveal tumours DAMATO B-Liverpool
15:00	1363 Management of retinal tumours DESJARDINS L-Paris
15:15	1364 Management of conjunctival tumours MIDENA E-Padova
15:30	<b>Break</b>
15:45	1365 Lid tumours SERGARD S-Stockholm
16:00	1366 Orbital tumours PRAUSE JU-Copenhagen



Saturday, 16:40 - Hall Europa A

Remember to attend the General Assembly

- ... to witness the award ceremony
- ... to provide feedback to the organisers
- ... to meet the Board
- ... to express your opinion
- ... to hear the results of the elections



**Welcome**  
17:00 – 17:15  
**Europa A**

**Welcome by the President EVER 2009**  
Charles RIVA - President



**EVER Lecture**  
17:20 – 18:00  
**Europa A**

**Corneal surface regeneration: epithelial sheets to epithelial crypts**  
Harminder DUA - Nottingham, UK  
Introduction by Charles RIVA



**European Ophthalmologic Heritage Lecture**  
18:05 – 18:20  
**Europa A**

**Hans Goldmann (1899 – 1991) – the man who coined the daily practice of ophthalmology worldwide during half a century until today**  
Balder P. GLOOR - Zürich, Switzerland  
Introduction by Tero KIVELÄ  
In collaboration with the Academia Ophthalmologica Internationalis



**EVER-Acta Lecture**  
18:25 – 19:00  
**Europa A**

**From intravitreal cell-encoated drug therapy to low-(brain-)pressure-glaucoma**  
Jost JONAS - Mannheim, Germany  
Introduction by Einar STEFANSSON



**Social**  
19:00 -20:00  
**Europa C**

**Opening concert given by Irena Preda (soprano) & Marko Hatlak (accordeon)**



NOVARTIS  
OPHTHALMICS

**Social**  
20:00 -21:30  
**S. Bernardin**

**EVER Welcome reception with musical entertainment**







**Thursday  
October 1, 2009**



<b>Europa A</b>	<b>EURETINA Session: development of the OCT technology and its application</b>			08:15 – 09:45
Joint M.	Rui BERNARDES			
				
08:15	2111	Segmentation of FD-OCT images shows selective loss of inner retinal layers in patients with DM and no or early DR VERBRAAK FD-Amsterdam		
08:33	2112	Assessing macular edema- prognostic parameters by OCT DE SMET M-Lauzanne		
08:51	2113	Cirrus HD OCT algorithms for macula and retinal nerve fiber analysis HORNE M-Dublin, CA		
09:09	2114	High-definition Fourier domain OCT: non-invasive assessment of BRB changes BERNARDES R, SANTOS T, CUNHA-VAZ J-Coimbra		
09:27		Discussion		
<b>Europa B</b>	<b>PBP: Apoptosis and angiogenesis in retinal neurovascular degeneration: can it be prevented?</b>			08:15 – 09:45
SIS	Paulo DE SOUZA-RAMALHO			
08:15	2121	Diabetic retinopathy - Apoptosis and BRB breakdown prevention in early diabetic retinopathy DE SOUZA-RAMALHO P, PEREIRA DA SILVA A, PEGO P, BICHO MP-Lisbon		
08:33	2122	The role of HIF-1 alfa in apoptosis and proliferative retinopathy FERNANDES R, BENTO C, MATAFOME P, SEIÇA R, PEREIRA P-Coimbra		
08:51	2123	The effects of sub-conjunctival EPO administration on ERG and on the peripheral blood hematocrit in animal model (rabbit) DELGADO E, RESENDE AP, SAO-BRAS B, DE SOUZA-RAMALHO P-Lisbon		
09:09	2124	Tolerance and safety of ocular use of recombinant human erythropoietin (rhEPO). Neuroprotective effects in ocular hypertension/glaucoma GOMES N, ROCHA DE SOUSA A, FALCAO REIS F, SONG BJ, DEL PRIORE LV-Porto, New York		
09:27	2125	Intravitreal and plasmatic levels of erythropoietin after sub-conjunctival administration in rabbits RESENDE AP, DELGADO E, SAO-BRAS B, DE SOUZA-RAMALHO P-Lisbon		
<b>Emerald I</b>	<b>ACB: New concepts for tissue reconstruction in RPE</b>			08:15 – 09:45
SIS	Hannu UUSITALO, Kai KAARNIRANTA			
				
08:15	2131	The clinical potential of RPE cells in retinal repair DA CRUZ L-London		
08:45	2132	Stem cell applications for retinal pigment epithelial cell defects SKOTTMAN H-Tampere		
09:15	2133	Biomaterials for RPE tissue engineering and cell microencapsulation URTTI A-Kuopio		
<b>Adria</b>	<b>NSPH: Visual function following prematurity and/or very low birth weight - What can we learn from the past for the future?</b>			08:15 – 09:45
SIS	Lene MARTIN			
08:15	2161	Visual and cognitive function in adolescents born with very low birth weight - a 15-year follow-up HELLGREN K-Stockholm		
08:33	2162	Ocular motor development in normal and premature children YGGE J-Stockholm		
08:51	2163	Eye alignment in low birth weight and/or prematurity ARING E-Göteborg		
09:09	2164	Visual impairment in children born before 25 gestational weeks - boys are more vulnerable than girls JACOBSON L-Stockholm		
09:27	2165	Update on risk factors and future perspectives for preterm infants HELLSTRÖM A-Göteborg		

<b>Emerald II MBGE: Free Papers 1</b>			08:15 – 09:45
FP	Bart LEROY, Amanda CHURCHILL		
08:15	2141	Regulation of retinal ganglion cell gene expression by bHLH transcription factors in the developing and ischemic retinas MATTER JM, CHIODINI F, DELAFOSSE L, MATTER-SADZINSKI L, POURNARAS CJ–Geneva	
08:27	2142	The distribution of neuroglobin in mouse eye YOU Y, DEWILDE S, VAN DE VEIRE S, VAN BERGEN T, VANDEWALLE E, MOONS L, MOENS L, STALMANS I–Leuven, Antwerp	
08:39	2143	Role of inflammation-related gene polymorphisms in branch retinal vein occlusion WEGER M, STEINBRUGGER I, RENNER W, MAIER R, WEDRICH A, SCHMUT O, HAAS A–Graz	
08:51	2144	Morphological and functional characteristics of the hyperautofluorescent parafoveal ring in retinitis pigmentosa LENASSI E, POPOVIC P, PEROVSEK D, HAWLINA M–Ljubljana	
09:03	2145 <i>rf</i>	Gene therapy mediates cone rescue and rejuvenation in the R91W mutant form of Rpe65-deficiency mice ARSENIEVIC Y, CRIPPA S, PIGNAT V, SAMARDZIJA M, KOSTIC C–Lausanne, Zurich	
09:09	2146 <i>rf</i>	Importance of electroretinogram in bull's eye maculopathy HALFELD FURTADO DE MENDONCA R, KOK F, ROSEMBERG S, YUKIHIKO TAKAHASHI W–São Paulo	
09:15	2147 <i>rf</i>	LOC387715/ARMS2 studies – gene sequencing as a procedure of choice WYLEGALA E, TEPER S, NOWINSKA A–Katowice	
09:21	2148 <i>rf</i>	Hunter's syndrome and buphthalmos in a girl: an unusual ophthalmic association SETHI S, BHARTIYA S, MEHTA M, CHANDRA M, GHOSE S–Delhi	

<b>Mediterranea I G: Ocular Rigidity: Biomechanical aspects and clinical applications</b>			08:15 – 09:45
SIS	Konstantin KOTLIAR		
			supported by 
08:15	2151	Why do we need a biomechanical approach to the ocular rigidity concept? KOTLIAR KE, KOSHITS IN, BAUER S, LOHMANN CP, LANZL IM–Munich, St. Petersburg	
08:30	2152	Biomechanical models for clinical data analysis of pressure-volume relationship in the human eye BAUER S, KOTLIAR KE, STEIN A, VORONKOVA E–St. Petersburg, Munich, Moscow	
08:45	2153	Ocular rigidity in living human eyes in health and disease PALLIKARIS IG–Heraklion	
09:00	2154	Ocular rigidity and ocular response analyzer IOMDINA E, ARUTUNIAN L, IGNATIEVA N, DANILOV N–Moscow	
09:15	2155	Evidence for altered ocular rigidity in glaucoma SCHMETTERER L, GARHOFER G–Vienna	
09:30	2156	Ocular pulse amplitude under pressure: what happens to OPA in glaucoma before and after surgery? STALMANS I, ZEYEN T, BREUSEGEM C–Leuven	
Daphnia	<b>COS: KPro cornea</b>		
FP	Christopher LIU		
08:15	2171	A new tissue-polymer hybrid drug delivery system for artificial corneas SHEN T, BARRETT R, GARTY S, KANAYAMA S–Seattle	
08:27	2172	Evaluation of anterior chamber depth in aphakic and pseudophakic patients with Boston type 1 keratoprosthesis DE LA CRUZ J, GUPTA S, ELDERKIN S, GARCIA J–Chicago, New York	
08:39	2173 <i>rf</i>	Retinal detachments after Boston keratoprosthesis: incidence, predisposing factors and outcomes of repair JARDELEZA MS, DOHLMAN CH, YOUNG L–Boston	
08:45	2174 <i>rf</i>	Prospective evaluation of the Boston keratoprosthesis AMENT JD, PINEDA R, TILAHUN Y, BEHLAU I, DOHLMAN CH–Boston, Addis Ababa	
08:51	2175 <i>rf</i>	Cost-effectiveness of the Boston keratoprosthesis AMENT JD, STRYJEWSKI TP, DOHLMAN CH–Boston	
08:57	2176 <i>rf</i>	Boston keratoprosthesis with titanium back plate DOHLMAN CH, TODANI A, AMENT JD, CHODOSH J, CIOLINO J, COLBY K, PINEDA R, BELIN M, AQUAVELLA J, GRANEY J–Boston, Albany	

**Keynote Lecture 1 Pathogen interactions in the pathogenesis of endophthalmitis**

10:00 – 10:45

**Europa A**

Michael GILMORE - Boston, USA

Introduction by Constantin POURNARAS



<b>Europa A</b>	<b>RV: Visualization techniques of the retina</b>	11:00 – 12:30
FP	Frank VERBRAAK, Carl ARNDT	
11:00	2211 Macular thickness alterations after cataract surgery determined by optical coherence tomography ELEFTHERIA DOU M, FRAGISKOU S, KYMIONIS G, PAPADAKI T, PANTELEONTIDIS V, PALLIKARIS IG, TSILIMBARIS M–Heraklion	
11:12	2212 Slitlamp integrated OCT, what you can see, is what you can scan VERBRAAK FD, STEHOUWER M, DEVRIES H, VAN LEEUWEN TG–Amsterdam, Capelle a/d IJssel	
11:24	2213 Scanning beyond the limits of standard OCT: OCT scans of the peripheral retina and the anterior chamber angle with a slitlamp integrated FD-OCT system STEHOUWER M, VERBRAAK FD, DE VRIES H, VAN LEEUWEN TG–Amsterdam, Capelle a/d IJssel	
11:36	2214 Screening for retinal detachment using a wide field scanning laser ophthalmoscope BONNAY G, NGUYEN F, NABHOLZ N, BOUSQUET E, DUCASSE A, ARNDT C–Reims, Montpellier	
11:48	2215 Optical coherence tomography and biomicroscopical analysis in macular holes <i>rf</i> FRUSCHELLI M, MOTOLESE I, MOTOLESE PA, FREZZOTTI P, MOTOLESE E–Siena, Grosseto	
<b>Europa B</b>	<b>PBP: Physiology-Biochemistry-Pharmacology 1</b>	11:00 – 12:30
FP	Paul BISHOP, Leopold SCHMETTERER	
11:00	2221 Does internal longitudinal microstructure of retinal veins change with age in medically healthy persons? KOTLIAR KE, KHAROUBI A, SCHMIDT-TRUCKSÄSS A, HALLE M, LANZL IM–Munich, Basel	
11:12	2222 The AMD-associated complement factor H (CFH) polymorphism Y402H results in decreased CFH localisation to Bruch's membrane BISHOP PN, ZAMBRANO I, MORGAN BP, HAKOBYAN S, DAY AJ, CLARK SJ–Manchester, Wales	
11:24	2223 Lornoxicam pharmacokinetics in the vitreous humor of albino rabbits TSIKA C, TSOURDOU A, TZATZARAKIS M, TSILIMBARIS M, PALLIKARIS IG–Heraklion	
11:36	2224 Subconjunctival injection of bevacizumab (Avastin®) for corneal neovascularization DE LA PAZ MF, DE SOUSA F, PONCE C, ALVAREZ J, BARRAQUER RI–Barcelona	
11:48	2225 Activity of corneal nociceptive nerve fibers during allergic challenge of the ocular surface GALLAR J, ACOSTA MC, LUNA C, BELMONTE C–Sant Joan d'Alacant	
12:00	2226 <i>rf</i> Cytochrome C oxidase expression in retinal rod outer segment disks BARABINO S, PANFOLI I, CALZIA D, ROLANDO M, MORELLI A–Genoa	
12:06	2227 <i>rf</i> Vasopressin receptors in ocular tissues and their impact on ocular hydrodynamics BOGNER B, TOCKNER B, RUNGE CW, STROHMAIER C, GRABNER G, REITSAMER HA–Salzburg	
<b>Emerald I</b>	<b>ACB: Ocular anatomy and cell biology</b>	11:00 – 12:30
FP	Nadja KNOP, Yvan ARSENIEVIC	
11:00	2231 The neuromuscular junction microenvironment in extraocular and limb muscles PEDROSA DOMELLO F, BRÖNNSTRÖM T, ANDERSEN PM, MARKLUND SL, LIU J–Umeå	
11:12	2232 Keratinisation status and cytokeratins of the human Meibomian gland epithelium KNOP E, LUDESCHER M, KNOP N–Berlin, Hannover	
11:24	2233 In search for correlation among markers for limbal stem cells niche CURCIO C, CALIENNO R, LANZINI M, IEZZI M, MARIOTTI M, COLESANTI M, NUBILE M–Chieti	
11:36	2234 Chromosomal number aberrations and transformation in adult mouse retinal stem cells in vitro DJOJOSUBROTO M, BOLLLOTTE F, WIRAPATI P, RADTKE F, STAMENKOVIC I, ARSENIEVIC Y–Lausanne	
11:48	2235 Hypertonicity-induced decrease in aquaporin-4 expression in retinal pigmented epithelial cells WILLERMAIN F, PIENS I, JANSENS S, ARSENIEVIC T, OP DE BEEK A, MAKHOUL M, BOLAKY N, CASPERS L, PERRET J, DELPORTE C–Bruxelles	
12:00	2236 The Bmi1 polycomb gene as a target for therapies against retinal degeneration ARSENIEVIC Y, VAN LOHUIZEN M, ZENCAK D–Lausanne, Amsterdam	
<b>Emerald II</b>	<b>MBGE: Genotypes and phenotypes</b>	11:00 – 12:30
FP	Jochen GRAW, Marzena GAJECKA	
11:00	2241 Splicing defect in Calpain12 cDNA of a recessive cataract mutation in rats (cat) <i>rf</i> GRAW J–Neuherberg	
11:12	2242 Genomic (epigenetic) DNA methylation in patients with open-angle glaucoma JÜNEMANN A, LENZ B, REULBACH U, SCHLÖTZER-SCHREHARDT U, REJDAK R, KORNHUBER J, KRUSE F, BLEICH S–Erlangen, Hannover	
11:24	2243 Phenotype-genotype relationship of TGFβ1 corneal dystrophies among Polish families NOWINSKA A, WYLEGALA E–Katowice	
11:36	2244 Gene screening at the 13q32 keratoconus locus <i>rf</i> GAJECKA M–Poznan	
11:48	2245 A novel congenital Stargardt-like macular dystrophy BITOUN P, PIPIRAS E, RIGAUDIERE F, AUDO I, MEYER M, BENZACKEN B, DELAHAYE A–Bondy, Paris, Savigny s/o	
12:00	2246 Analysis of SERPING1 and its association with age-related macular degeneration CARTER JG, CHURCHILL AJ–Bristol	

Mediterranea I	<b>G: Monitoring glaucoma patients: visual field and imaging</b>	11:00 – 12:30
FP	Thierry ZEYEN, Jost JONAS	
11:00	2251	Until what age should glaucoma be monitored and/or treated? A novel index that facilitates clinical decision making JANSONIUS N, WESSELINK C, STOUTENBEEK R–Groningen
11:12	2252	Relationship between standard automated perimetry and high-resolution optical coherence tomography in glaucoma patients CALVO PEREZ P, FERRERAS A, ABADIA B, PABLO LE, PAJARIN AB, LARROSA JM–Zaragoza
11:24	2253	RTVue Fourier-domain OCT: reproducibility of RNFLT and macular thickness measurements GARAS A, KOTHY P, HOLLO G–Budapest
11:36	2254	Retinal nerve fiber layer thickness and central corneal thickness in ocular hypertensive patients and healthy subjects BRON AM, MUSELIER A, BEYNAT J, CREUZOT C–Dijon
11:48	2255	Rabbit visual field follow-up in pediatric glaucoma MARTIN L, LUNDVALL NILSSON A–Stockholm
11:54	2256	The retinal nerve fiber layer and the optic nerve head morphology after glaucoma surgery GRACNER T, PAHOR D–Maribor

Adria	<b>NSPH: Neuro-ophthalmology and Immunology</b>	11:00 – 12:30
FP	François-Xavier BORRUAT, Piergiorgio NERI	
11:00	2261	Toxic effect of vigabatrin on retinal nerve fiber layer MIDELFART A, MOSENG L, SAETER M–Trondheim
11:12	2262	Preterm and at term children: morphological and functional analysis of optic nerve and visual pathway with OCT, HRT and pVEP ANGELI R, RUBERTO G, GUAGLIANO R, BERTONE C, BARILLA D, TRAVERSA E, SUZANI M, RUSTIONI G, PICCININI P, TINELLI C, VANELLI G, MILANO G, BIANCHI PE–Pavia
11:24	2263	Studying electrophysiological characteristics in children with congenital sensory nystagmus- case presentations BRECELJ J, STIRN-KRANJC B–Ljubljana
11:36	2264	Zone-I retinopathy of prematurity, progression and scheduling of treatment AKKOYUN I, OTO S, YILMAZ G, TARCAN A, AKOVA AY–Ankara
11:42	2265	A new technique of anterior TAP enhances the positivity of CMV by PCR in hypertensives anterior uveitis KOCH P, LIESNARD C, JUDICE L, MAKHOUL D, WILLERMAIN F, CASPERS L–Brussels
11:54	2266	Efficacy of systemic ganciclovir as a therapeutic strategy for cytomegalovirus-associated anterior uveitis in immunocompetent patients ANGI M, CASSOUX N, FARDEAU C, LE HOANG P, BODAGHI B–Paris
12:06	2267	Foveal serous detachment in juvenile Idiopathic arthritis (JIA)-associated uveitis LIANG F, TERRADA C, DUCOS DE LAHITTE G, QUARTIER P, LEHOANG P, BODAGHI B–Paris

Daphnia	<b>COS: Keratoconus and corneal grafting</b>	11:00 – 12:30
FP	Harminder S DUA, Jean-Jacques GICQUEL	
11:00	2271	Can the corneal endothelium of the pig proliferate in vivo? NICHOLLS S, BAILEY M, MITCHARD L, DICK AD–Bristol
11:12	2272	Visual outcomes and safety of Intacs versus KeraRing intracorneal ring segment implantation in keratoconus CANADAS SUAREZ P, HERNÁNDEZ-VERDEJO J, MARINA C, TEUS-GUEZALA M–Madrid
11:24	2273	A new storage medium for pre-cut donor tissue for DSAEK in eye bank POCOBELLIS A, AMATO D, DUCOLI P–Rome
11:36	2274	Effect of corneal collagen crosslinking on corneal sensitivity, tear function and innervation: a clinical and confocal microscopic study KONTADAKIS GA, KYMIONIS G, PORTALIOU D, DIAKONIS V, PALLIKARIS IG–Heraklion
11:48	2275	Results of amniotic membrane transplantation with diathermocoagulation for corneal hydrops secondary to keratoconus. MILKA M, WYLEGALA E–Katowice
12:00	2276	DSAEK grafted corneas remain clear with low endothelial cell counts OLESEN H–Copenhagen
12:12	2277	Comparison of deep anterior lamellar keratoplasty results in different TGF $\beta$ I corneal dystrophies. NOWINSKA A, WYLEGALA E–Katowice

Submit your next paper to the  
EVER Journal,  
Acta Ophthalmologica



Europa A

Ocular surface, what's new in 2009?		12:35 – 13:35
Alain BRON		
12:35	Introduction	
12:41	Prophylaxis in ocular surgery BRON AM-Dijon	
12:53	Meibomian gland dysfunction: management and treatment DOAN S-Paris	
13:05	A new treatment for Meibomian gland dysfunction PURSLOW C-Birmingham	
13:17	The prophylactic and therapeutic efficacy of a new eye drop for the treatment of murine dry eye induced by intelligently controlled environmental system ZHANG X-WenZhou	
13:29	Conclusions	
13:35	End of session	

<b>Europa A</b>	<b>RV: In vivo imaging of cellular dynamics in the eye</b>	13:45 – 15:15
SIS	Michel PAQUES	
13:45	2311	In vivo imaging of microglial cell trafficking PAQUES M, SIMONUTTI M, SAHEL J-Paris
14:15	2312	In vivo imaging of retinal inflammation in experimental autoimmune uveoretinitis XU H-Aberdeen
14:45	2313	In vivo confocal microscopic evaluation of inflammatory changes in the ocular surface LABBE A, BAUDOUIN C-Paris
<b>Europa B</b>	<b>PBP: Nitric oxide in the healthy and unhealthy eye</b>	13:45 – 15:15
SIS	Leopold SCHMETTERER, Neville OSBORNE	
13:45	2321	Role of NO in retinal vascular disease SCHMETTERER L-Vienna
14:03	2322	Introduction on the multifaceted roles of nitric oxide in the retina OSBORNE NN-Oxford
14:21	2323	Interventions via the NO system and tachyphylaxis PRASANNA G-San Diego
14:39	2324	Nitric oxide and inflammation DICK AD-Bristol
14:57	2325	Nitric oxide and cGMP protect the retina from ischemia and mediate somatostatin's neuroprotective effects THERMOS K, KIAGIADAKI F, MASTRODIMOU N-Heraklion
<b>Emerald I</b>	<b>ACB: The Meibomian gland - revisited: anatomy, physiology and contribution to ocular surface disease</b>	13:45 – 15:15
SIS	Erich KNOP, Nadja KNOP, Anthony J. BRON	
13:45	2331	Anatomy of the Meibomian gland KNOP E, KNOP N-Berlin, Hannover
14:03	2332	Physiological impact of the Meibomian gland on ocular surface integrity BRON AJ-Oxford
14:21	2333	Keratinisation of the Meibomian gland as an important factor in Meibomian gland dysfunction (MGD) KNOP N, KNOP E-Hannover, Berlin
14:39	2334	New insights into Meibomian gland function from gene expression experiments SCHIRRA F, SEITZ B-Homburg/Saar
14:57	2335	Pathological alterations in Meibomian gland dysfunction as an important factor in ocular surface disease BARABINO S-Genoa
<b>Emerald II</b>	<b>MBGE: Genes and markers in AMD</b>	13:45 – 15:15
SIS	Marcela VOTRUBA, Albert EDWARDS	
13:45	2341	The role of SERPING1 in age related macular degeneration LOTERY AJ, ENNIS S, GIBSON J, CREE A, HARRIS C, MORGAN P-Southampton, Cardiff
14:00	2342	CFH, C3 and ARMS2 are significant risk loci for age-related macular degeneration but not for late stage disease progression SCHOLL HPN-Bonn
14:15	2343	Genetic influences on biomarkers in AMD CHONG V-Oxford
14:30	2344	Functional genomics of systemic complement activation in AMD EDWARDS AO-Rochester
14:45	2345	Can diet reduce the genetic risk of AMD? KLAVER C-Rotterdam
15:00	2346	Individualised risk in AMD MACKEY D-Nedlands

Mediterranea I	<b>G: Blood flow in glaucoma - new horizons</b>	13:45 – 15:15
SIS	Ingeborg STALMANS, Selim ORGUL	

**Alcon®**

13:45	2351	Ocular blood flow autoregulation and the clinical implications of its alteration GARHOFER G-Vienna
14:07	2352	Most readily usable methods to measure ocular blood flow GUGLETA K-Basel
14:29	2353	Disease mechanisms leading to impaired blood flow in glaucoma GHERGHEL D-Birmingham
14:51	2354	Impact of medication on ocular blood flow SCHMETTERER L-Vienna

Adria	<b>NSPH: Management in pediatric ophthalmology</b>	13:45 – 15:15
SIS	Dominique BREMOND-GIGNAC, Solange MILAZZO	

**Alcon®**

13:45	2361	Recent developments of glaucoma in children NISCHAL KK-London
14:03	2362	Recent developments of dry eye in children BREMOND-GIGNAC D-Amiens
14:21	2363	Management of neuro-ophthalmology cases in children MILAZZO S-Amiens
14:39	2364	Recent developments of ocular allergy in children CHIAMBARETTA F-Clermont Ferrand
14:57	2365	Recent developments in retinopathy of prematurity MORTEMOUSQUE B-Bordeaux

Daphnia	<b>CONCORDIA: Designing effective courses for European residents and teachers in ophthalmology</b>	13:45 – 15:15
Workshop	Marko HAWLINA, Werner SPILEERS, Charles RIVA	<b>in CONCORDIA pro VISU</b>

13:45	2371	Concordia pro visu: initiative, purpose and developments KIVELÄ T-Helsinki
14:00	2372	EBO, ENET and accredited courses TASSIGNON MJ-Antwerp
14:15	2373	EUPO courses SPILEERS W-Leuven
14:30	2374	SOE and its role in Concordia SEREGARD S-Stockholm
14:45	2375	EVER and emphasis of research in teaching RIVA CE-Bologna
15:00	2376	Current methods of teaching ocular microsurgery ZAGORSKI ZF-Lublin

<b>EVI Award Lecture</b> 15:30 – 16:10 <b>Europa A</b>	<b>Common or individual molecular mechanisms underlying different forms of retinal degeneration</b> EVA awardee 2009: Valeria MARIGO PhD - Modena, Italy Introduction by Eberhard ZRENNER	
--	---	---

<b>Poster session 1</b> 16:15 - 17:25 <b>Europa C</b> see pages 32-33	<b>Anatomy/Cell Biology - Glaucoma - Molecular Biology/Genetics/Epidemiology - Physiology/Biochemistry/Pharmacology</b> Saeed AKHTAR, Roberto GALLEGOS-PINAZO, Luc MISSOTTEN, Gijs VRENSEN, Gerhard GARHOFER, Gabriele FUCHSJÄGER-MAYRL, Marcela VOTRUBA, Amanda CHURCHILL, Neville OSBORNE, Leopold SCHMETTERER
--	---

<b>Europa A</b>	<b>RV: Alternative applications for anti-VEGF therapy and PDT</b>	17:30 – 19:00
FP	Hansjuergen T. AGOSTINI, Jean - Jacques DE LAEY	
17:30	2411 Management of macular edema due to branch retinal vein occlusion with intravitreal injections of pegaptanib sodium GALLEGU-PINAZO R, DIAZ-LLOPIS M, FRANCES-MUNOZ E, UDAONDO-MIRETE P, SALOM D, SANZ-MARCO E, LOPEZ-PRATS M, GARCIA-DELPECH S-Valencia	
17:42	2412 Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses MONTERO MORENO JA, RUIZ-MORENO JM-Valladolid, Albacete	
17:54	2413 VEGF is reduced in breast milk after intravitreal injection of bevacizumab EHLKEN C, STAHL A, AGOSTINI HT-Freiburg	
18:06	2414 Inflammatory factors in experimental retinal vein occlusion REHAK M, HOLLBORN M, IANDIEV I, PANNICKER T, WIEDEMANN P, BRINGMANN A-Leipzig	
18:18	2415 Low dose verteporfin (1.5mg/m <sup>2</sup> ) in chronic idiopathic central serous chorioretinopathy SETROUK E, GARCIA T, DUCASSE A, ARNDT C-Reims	
18:30	2416 Apoptotic activity of intravitreal bevacizumab on rabbit retina <i>rf</i> TURKCU MF, ALP MN, TURKCU G, KULACOGLU S, KURAL G-Ankara	
18:36	2417 Intravitreal bevacizumab as primary local treatment for choroidal neovascularization secondary to uveitis <i>rf</i> JULIAN K, FARDEAU C, TERRADA C, FRANCAIS C, LEHOANG P, BODAGHI B-Paris	
18:42	2418 Photodynamic therapy for symptomatic circumscribed choroidal hemangioma <i>rf</i> MAYER CF, WACKERNAGEL W, LACKNER EM, SCHNEIDER MR, HAAS A, WEGER M, LANGMANN G-Graz	

<b>Europa B</b>	<b>PBP: Physiology-Biochemistry-Pharmacology 2</b>	17:30 – 19:00
FP	Neville OSBORNE, Herbert REITSAMER	
17:30	2421 Effect of nitric oxide synthase inhibition and nerve stimulation frequency on autonomous choroidal vasodilation REITSAMER HA, BOGNER B, RUNGE CW, BRANDTNER H, STROHMAIER C, KIEL JW-Salzburg, San Antonio	
17:42	2422 Microstructural alterations of the retinal arterial blood column along the vessel axis in healthy volunteers with age LANZL IM, KHAROUBI A, SCHMIDT-TRUCKSÄSS A, HALLE M, KOTLIAR KE-Munich, Basel	
17:54	2423 Effect of breathing a mixture of 92% O <sub>2</sub> + 8% CO <sub>2</sub> on flicker induced vasodilatation LASTA M, PEMP B, GARHOFER G, SCHMETTERER L-Vienna	
18:06	2424 Effects of moxaverine on ocular blood flow in patients with age-related macular degeneration, patients with primary open angle glaucoma and in healthy controls PEMP B, GARHOFER G, LASTA M, SCHMIDL D, SCHMETTERER L-Vienna	
18:18	2425 Effect of glaucoma and glaucoma risk factors on choroidal hemodynamics ABOU SAMRA W, RIVA CE, POURNARAS CJ, EMARAH M-Mansoura, Sion, Geneva	
18:30	2426 <i>rf</i> In vitro transcorneal and transscleral diffusion of radiolabeled compounds in human and rabbit cornea and in human, monkey, dog, and rabbit sclera STRUBLE CB, EDELHAUSER HF, HOLLEY GP, GROSSNIKLAUS HE-Madison, Atlanta	
18:36	2427 <i>rf</i> Consequences of dietary omega-3 polyunsaturated fatty acid deficiency on retinal function and intraocular pressure in the rat BARDET B, ACAR N, CREUZOT C, BRON AM, BRETILLON L-Dijon	

<b>Emerald I</b>	<b>COS: Wavefront aberrometry and adaptive optics</b>	17:30 – 19:00
SIS	Jean-Jacques GICQUEL, Pierre Jean PISELLA	
17:30	2431 Visual function after cataract surgery in patients with an aspherical lens without spherical aberration PISELLA PJ-Tours	
17:45	2432 Wavefront aberrometry advances in refractive surgery COCHENER B-Brest	
18:00	2433 Wavefront aberrations variations with accommodation GICQUEL JJ-Poitiers	
18:15	2434 Adaptive optics applied to the vision simulator CHATEAU N-Orsay	
18:30	2435 Custom wavefront contact lenses LOPEZ-GIL N-Murcia	
18:45	2436 Colorimetric comparison between different filtered IOLs and human crystalline lenses at various ages MENCUCCI R, MENCHINI U, ROMANO G, MONICI M, FUSI F, GUASTI A, MERCATELLI L-Florence	

<b>Emerald II MBGE: Free Papers 3</b>			17:30 – 19:00
FP	Seang-Mei SAW, Marcela VOTRUBA		
17:30	2441	The effect of upregulated LOX and LOXL2 on inflammation and fibrosis in a laser induced CNV model VAN DE VEIRE S, VAN BERGEN T, VANDEWALLE E, MOONS L, SMITH V, OGG S, STALMANS I-Leuven, Palo Alto	
17:42	2442	Is inhibition of VEGF165 sufficient to inhibit scar formation after trabeculectomy? VAN BERGEN T, VAN DE VEIRE S, VANDEWALLE E, MOONS L, STALMANS I-Leuven	
17:54	2443	Intraocular pressure and associated factors in a Central Indian population. The Central India Eye and Medical Study JONAS JB, NANGIA V, MATIN A, SINHA A, KULKARNI M, BHOJWANI K-Mannheim, Nagpur	
18:06	2444	Screening history in those requiring fast track referral for proliferative diabetic retinopathy (PDR) in the ni diabetic retinopathy screening programme HART PM, SAXENA R, JOHNSTON SE, FLYNN C, MCEDUFF P-Belfast	
18:18	2445	Frequency of pterygium in indigenous Kadiweu VERONESE RODRIGUES ML, SALUM TG-Ribeirão Preto/São Paulo, Campo Grande/Mato Grosso do Sul	
18:30	2446 <i>rf</i>	Relationship between IOP and age in the Salzburg-Moorfields-Collaborative Glaucoma Study REITSAMER HA, HITZL W, WINTERSTELLER CH, HORNYKEWYCS K, ABRI S, GRABNER G-Salzburg	
18:36	2447 <i>rf</i>	Major eye diseases and risk factors associated with systemic hypertension in an adult chinese population: the Beijing Eye Study LIBONDIT T, JONAS JB, WANG S, XU L, WONG TY, CUI T, LI Y, YANG H, CONG S-Mannheim, Beijing, Melbourne	
<b>Mediteranea I G: Pressure and blood flow in glaucoma</b>			17:30 – 19:00
FP	Carlos MARQUES-NEVES, Anna-Maria STEVENS		
17:30	2451	Aging and glaucoma PILLUNAT L-Dresden	
17:42	2452	Association between optic nerve head blood flow as assessed with Laser Doppler Flowmetry and mean arterial blood pressure in glaucoma, ocular hypertension and healthy control subjects SCHMIDL D, HOMMER A, RESCH H, FUCHSJAEGER-MAYRL G, GARHOFER G, VASS C, SCHMETTERER L-Vienna	
17:54	2453 <i>rf</i>	Vascular endothelial dysfunction in primary open angle glaucoma CELLINI M, GIZZI C, STROBBE E, FAVARETTO E, FILIPPINI M, PALARETI G, CAMPOS EC-Bologna	
18:00	2454 <i>rf</i>	Sympathetic influence on intraocular pressure MARQUES-NEVES C, GONÇALVES C, LARANJO S, SANTOS M, ROCHA I-Lisbon	
18:06	2455 <i>rf</i>	Sympathetic variability of intraocular pressure of glaucoma patients evaluated by wavelets MARQUES-NEVES C, GONÇALVES C, LARANJO S, SANTOS M, FIGUEIREDO A, ROCHA I-Lisbon	
18:12	2456 <i>rf</i>	Measurement of IOP with radiowave telemetry TODANI A, FAVA M, BEHLAU I, MELKI S, DOHLMAN CH-Boston	
18:18	2457 <i>rf</i>	Factors affecting ocular rigidity in normal human eyes DASTIRIDOU AI, GINIS H, KARYOTAKIS NG, TSILIMBARIS M, PALLIKARIS IG-Heraklion	
18:24	2458	Sensitivity of applanation tonometry readings to the geometrical parameters of the sclera and the shape of the cornea VORONKOVA E, BAUER S, TIPYASEV A-St-Petersburg	
<b>Adria RV: Retinal oxygenation in health and disease</b>			17:30 – 19:00
SIS	Einar STEFANSSON, Constantin POURNARAS		
17:30	2461	Retinal oxygenation in diabetic retinopathy HARDARSON SH, OLAFSDOTTIR OB, KARLSSON RA, BEACH JM, EYSTEINSSON T, BENEDIKTSSON JA, STEFANSSON E-Reykjavik	
17:45	2462	Retinal photocoagulation and oxygenation POURNARAS CJ-Geneva	
18:00	2463	Retinal and optic nerve oxygenation and carbonic anhydrase inhibition LA COUR M, STEFANSSON E-Copenhagen, Reykjavik	
18:15	2464	Noninvasive oximetry and glaucoma OLAFSDOTTIR OB, HARDARSON SH, GOTTFREDSDOTTIR MS, HARRIS A, STEFANSSON E-Reykjavik, Indianapolis	
18:30	2465	Retinal vessel oximetry made simple and reliable - principle, performance and clinical results HAMMER M, SCHWEITZER D-Jena	
18:45	2466	Retinal vessel oximetry using sequential and 'snapshot' hyperspectral imaging MCNAUGHT A, HARVEY A, MUZO G, MORDANT D, ALLABOUD I, RITCHIE P-Cheltenham, Edinburgh	

**Daphnia EBO: Teaching the teachers**

17:30 – 19:00

Workshop Marko HAWLINA, Werner SPILEERS, Charles RIVA



17:30	2471	Need for training the trainers programme in harmonisation of education HAWLINA M-Ljubljana
17:42	2472	The role of the professor as leader and promotor of science PRAUSE JU-Copenhagen
17:54	2473	Needs from residents' perspective and SOE YO KHAWAJA A-London
18:06	2474	EBO curriculum development CREUZOT C-Dijon
18:18	2475	How to conduct a good viva voce? ACLIMANDOS W-London
18:30	2476	How to teach residents to teach and to select proper residents for this goal VASSILEVA P-Sofia
18:42	2477	Professionalism and appraisal DUA HS-Nottingham

EVER 2009 programme



## Anatomy/Cell Biology

Moderators: Saeed AKHTAR, Roberto GALLEG-PINAZO, Luc MISSOTTEN, Gijs VRENSEN

- 201 Magnetic resonance Imaging vs. ultrasound biometry in the equatorial plane in human eyes  
KUSNYERIK A, RESCH MD, WILKE R, KLOSE U, BODA K, NEMETH J, SUVEGES I, ZRENNER E-Budapest, Tuebingen, Szeged
- 202 The correlation between central corneal thickness, ocular and general parameters  
GALGAUSKAS S, GARLAITE O, JUODKAITE G, TUTKUVIENE J, ASOKLIS R-Vilnius
- 203 Comparison of the corneal thickness measured by anterior segment optical coherence tomography and specular microscope versus ultrasound pachymetry  
KRUKNYTYE R, GALGAUSKAS S, JUODKAITE G, PAJAUJIS M, GARLAITE O, ASOKLIS R-Vilnius
- 204 Ultrastructural features of tree shrew cornea-collagen fibrils and proteoglycans  
ALMUBRAD T, AKHTAR S, BRON AJ-Riyadh, Oxford
- 205 Treatment of ocular surface injuries by the transfer of limbal and mesenchymal stem cells growing on nanofibrous scaffolds  
HOLAN V, ZAJICOVA A, LENOVA A, POKORNA K, SVOBODOVA E, KRULOVÁ M-Prague
- 206 Changes in expression of matrix metalloproteinases 1 and 8 in corneal epithelial cells after UV irradiation  
ARDAN T, CEJKOVA J-Prague
- 207 The influence of pollen proteases on human conjunctival cells  
RABENSTEINER DF, SCHMUTZ O, SPREITZHOFER EM, TRUMMER G, WACHSWENDER C, KIRCHENGAST S, WEDRICH A-Graz
- 208 Trabecular meshwork contribution to the uveoscleral outflow  
KARLOVA E, ZLOTARYOV A, NIKOLAYEVA G-Samara
- 209 Cell connections between lens fibres in the posterior pole of human and bovine lenses  
VAN MARLE G, VRENSEN G, HOEBEN K-Amsterdam, Leiden
- 210 Human anterior lens capsule epithelial cell contractions  
ANDJELIC S, ZUPANČIČ G, PEROVŠEK D, HAWLINA M-Ljubljana
- 211 Macrogliial changes in ipsilateral and contralateral rat retina in experimental glaucoma  
RAMIREZ AI, SALAZAR JJ, DE HOZ R, ROJAS B, ALARCON-MARTINEZ L, SALINAS-NAVARRO M, VILLEGRAS-PEREZ MP, VIDAL-SANZ M, TRIVINO A, RAMIREZ JM-Madrid, Murcia
- 212 The human choroid possesses substance P and calcitonin gene-related peptide intrinsic neurons  
TRIVINO A, DE HOZ R, ROJAS B, SALAZAR JJ, RAMIREZ AI, GALLEG B, RAMIREZ JM-Madrid
- 213 Pleiotropic effects of statins on the morphology of choroidal endothelial cells and vascular smooth muscle cells in hypercholesterolemic rabbits  
RAMIREZ JM, ROJAS B, SALAZAR JJ, RAMIREZ AI, DE HOZ R, GALLEG B, TRIVINO A-Madrid
- 214 Retinal ganglion cells in culture induced to die by insults of hydrogen peroxide ( $H_2O_2$ ), rotenone and glutamate/buthionine sulfoxime (GB) are differentially protected by the flavonoids, epicatechin gallate (EG) epigallocatechin gallate (EGCG) and genistein  
TENGKU KAMALDEN TA, OSBORNE NN-Oxford
- 215 Proteasome inhibitor -induced protein aggregation is regulated via HSP90, HDACs and microtubulus stability in ARPE-19 cells  
KAARNIRANTA K, RYHÄNEN T, VIIRI J, UUSITALO H, SALMINEN A-Kuopio, Tampere
- 216 HSP70 and p62/SQSTM 1 regulate differently autophagy clearance in ARPE-19 cells  
VIIRI J, HYTTINEN J, RYHÄNEN T, SALMINEN A, KAARNIRANTA K-Kuopio
- 217 Human retinal pigment epithelium expressed tight junction markers in spheroid cultures  
PINILLA I, WRIGHT LS, GARCIA MARTIN E, GAMM DM, CUENCA NICOLAS-Zaragoza, Madison, Alicante
- 218 Inhibition of Notch pathway enhances photoreceptor commitment from cultured retinal stem cells  
MONTAVON P, ARSENIEVIC Y-Lausanne
- 219 A new potential pharmacological target in diabetic retinopathy: the HuR pathway  
AMADIO M, BUCOLO C, DRAGO F, GOVONI S, PASCALE A-Pavia, Catania

## Glaucoma

Moderator: Gerhard GARHOFER, Gabriele FUCHSJÄGER-MAYRL

- 220 Rarebit visual field follow-up in pediatric glaucoma  
rf MARTIN L, LUNDVALL NILSSON A-Stockholm
- 221 The retinal nerve fiber layer and the optic nerve head morphology after glaucoma surgery  
GRACNER T, PAHOR D-Maribor
- 222 Vascular endothelial dysfunction in primary open angle glaucoma  
rf CELLINI M, GIZZI C, STROBBE E, FAVARETTO E, FILIPPINI M, PALARETI G, CAMPOS EC-Bologna
- 223 Sympathetic influence on intraocular pressure  
rf MARQUES-NEVES C, GONÇALVES C, LARANJO S, SANTOS M, ROCHA I-Lisbon
- 224 Sympathetic variability of intraocular pressure of glaucoma patients evaluated by wavelets  
rf MARQUES-NEVES C, GONÇALVES C, LARANJO S, SANTOS M, FIGUEIREDO A, ROCHA I-Lisbon
- 225 Measurement of IOP with radiowave telemetry  
rf TODANI A, FAVA M, BEHLAU I, MELKI S, DOHLMAN CH-Boston
- 226 Factors affecting ocular rigidity in normal human eyes  
rf DASTIRIDOU AI, GINIS H, KARYOTAKIS NG, TSILIMBARIS M, PALLIKARIS IG-Heraklion
- 227 Correlation between Goldmann applanation tonometry and rebound tonometry in relation to central corneal thickness  
BRANDTNER H, HITZL W, STROHMAIER C, ABRI S, WINTERSTELLER CH, HOHENSIIN M, RUCKHOFER J, STOIBER J, GRABNER G, REITSAMER HA-Salzburg
- 228 On the dependence of outflow facility on Intraocular pressure in the living human eye  
KARYOTAKIS NG, GINIS H, LIMNOPOULOU A, DASTIRIDOU AI, TSILIMBARIS M, PALLIKARIS IG-Heraklion
- 229 IOP evaluation in glaucoma patients after phacoemulsification  
STOJANOVIC N, TSOLAKI F, GOGAKI E, SAKKIAS G, TACHIAOS P-Thessaloniki
- 230 Functional correlation between retinal sensitivity threshold values of standard automated perimetry in glaucoma  
GUERRI MONCLAS N, PRIETO CALVO E, EGEA ESTOPINAN MC, FERRERAS A, PABLO LE-Zaragoza
- 231 SITA-SWAP and SITA-SAP in glaucoma suspects  
MILANO G, BOSSOLEI L, COLOMBO M, BORDIN M, LANTERI S, RAIMONDI M, ROSSI G-Pavia
- 232 Relationship between frequency-doubling perimetry indices and optic nerve head parameters measured with the Heidelberg retina tomograph 3  
FERRERAS A, CALVO PEREZ P, PAJARIN AB, ABADIA B, FOGAGNOLO P, FIGUS M, PABLO LE-Zaragoza, Rome, Pisa
- 233 Relationship between the automated classification of Heidelberg retina tomograph and main indices of short-wavelength automated perimetry  
CALVO PEREZ P, FERRERAS A, PABLO LE, PAJARIN AB, POLO V-Zaragoza
- 234 Reproducibility of optic disc measurements acquired with spectral-domain optical coherence tomography  
FERRERAS A, CALVO PEREZ P, PAJARIN AB, FOGAGNOLO P, FIGUS M, PABLO LE-Zaragoza, Rome, Pisa
- 235 An analysis of retinal nerve fiber layer with ImageJ program  
KIM S, KIM H, SHON Y-Seoul
- 236 Differences in retinal nerve fiber layer measurements between time domain optical coherence tomograph (OCT) and spectral domain OCT in patients with type 1 diabetes without retinopathy  
IDOPIE M, GARCIA MARTIN E, PINILLA I, GIL-ARRIBAS L, FUERTES LAZARO M-Zaragoza
- 237 Glaucomatous optic neuropathy and oscillatory potentials in the ERG to long-duration stimuli  
KAZARYAN AA-Moscow
- 238 Anterior segment optical coherence tomography imaging of OculusGen<sup>TM</sup> implants in trabeculectomy blebs  
BOEY PY, NARAYANASWAMY A, ZHENG CE, TUN TA, HTOON HM, AUNG T-Singapore
- 239 Is subconjunctival inflammation associated with failure of filtering surgeries?  
VERONESE RODRIGUES ML, FORTES FURTADO JM, GARCIA SOARES E, DEGHAIDE NHS, FELIPE CROSTA D, DONADI EA, SILVA DE PAULA J-Ribeirão Preto / São Paulo

**Molecular Biology/Genetics/Epidemiology**

Moderators: Marcela VOTRUBA, Amanda CHURCHILL

- 240 Gene therapy mediates cone rescue and rejuvenation in the R91W mutant form of Rpe65-deficiency mice  
*rf*

ARSENIEVIC Y, CRIPPA S, PIGNAT V, SAMARDZIJA M, KOSTIC C-Lausanne, Zurich

- 241 Importance of electroretinogram in bull's eye maculopathy

*rf* HALFELD FURTADO DE MENDONCA R, KOK F, ROSEMBERG S, YUKIHIKO TAKAHASHI W-São Paulo

- 242 LOC387715/ARMS2 studies – gene sequencing as a procedure of choice  
*rf*

WYLEGALA E, TEPER S, NOWINSKA A-Katowice

- 243 Hunter's syndrome and bupthalmos in a girl: an unusual ophthalmic association  
*rf*

SETHI S, BHARTIYA S, MEHTA M, CHANDRA M, GHOSE S-Delhi

- 244 Relationship between IOP and age in the Salzburg-Moorfields-Collaborative Glaucoma Study  
*rf*

REITSAMER HA, HITZL W, WINTERSTELLER CH, HORNYKEWYCS K, ABRI S, GRABNER G-Salzburg

- 245 Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population: the Beijing eye study  
*rf*

LIBONDI T, JONAS JB, WANG S, XU L, WONG TY, CUI T, LI Y, YANG H, CONG S-Mannheim, Beijing, Melbourne

- 246 Nitric oxide synthesis is related to astroglial cell cycle in the mouse retina via p53 gene regulation

GALLEGOS-PINAZO R, DIAZ-LLOPIS M, RAMIREZ AI, SALAZAR JJ, RAMIREZ JM, ZANON-MORENO VC, PONS-VAZQUEZ S, PINAZO-DURAN MD-Valencia, Madrid

- 247 Screening history of those with severe visual impairment due to diabetic retinopathy

HART PM, HART PW, JACKSON AJ-Belfast, Manchester

- 248 Symmetry of retinopathy in the NI diabetic retinopathy screening programme NIDRSP

HART PM, STEVENSON MR-Belfast

- 249 Glucose-6-phosphate dehydrogenase (G6PD) deficiency and proliferative diabetic retinopathy in a Sardinian male population, Italy  
*rf*

PINNA A, CONTINI E, GIACOBONI M, CARTA A, SOLINAS G-Sassari, Parma

- 250 Genetic and phenotypic analyses of retinitis pigmentosa in northern Tunisia

CHEBIL A, LARGUECHE L, CHOUCENE I, BAKLOUTI K, MERDASSI A, ABDELHAK S, EL MATRI L-Tunis

- 251 Phenotype-genotype correlations of TGFBI in Asian patients

CHAI SM, VITHANA E, MEHTA J, TAN D, TIN A-Singapore

- 252 Central corneal thickness and its association with ocular and general parameters in Indians. Central India Eye and Medical Study

JONAS JB, NANGIA V, SINHA A, MATIN A, KULKARNI M-Mannheim, Nagpur

- 253 Differential association of cataract sub-types with obesity and FTO polymorphisms

LIM L, TAI E, AUNG T, TAY W, SAW SM, SEIELSTAD M, WONG TY-Singapore

- 254 A novel mitochondrial ND5 gene mutation m.13042G>A in Leber hereditary optic neuropathy

PAJTLER A, STIRN-KRANJC B, BRECELI J, HAWLINA M-Ljubljana

- 255 Severe ocular trauma cases: types and incidence

STOJANOVIC N, TSOLAKI F, TACHIAOS P-Thessaloniki

- 256 Ocular features and management in the mucopolysaccharidoses

PINELLO L, DE BELVIS V, MAZZAROLO M, SCARPA M-Padua

**Physiology/Biochemistry/Pharmacology**

Moderators: Neville OSBORNE, Leopold SCHMETTERER

- 257 Cytochrome C oxidase expression in retinal rod outer segment disks  
*rf*

BARABINO S, PANFOLI I, CALZIA D, ROLANDO M, MORELLI A-Genoa

- 258 Vasopressin receptors in ocular tissues and their impact on ocular hydrodynamics  
*rf*

BOGNER B, TOCKNER B, RUNGE CW, STROHMAIER C, GRABNER G, REITSAMER HA-Salzburg

- 259 In vitro transcorneal and transscleral diffusion of radiolabeled compounds in human and rabbit cornea and in human, monkey, dog, and rabbit sclera  
*rf*

STRUBLE CB, EDELHAUSER HF, HOLLEY GP, GROSSNIKLAUS HE-Madison, Atlanta

- 260 Consequences of dietary omega-3 polyunsaturated fatty acid deficiency on retinal function and intraocular pressure in the rat  
*rf*

BARDET B, ACAR N, CREUZOT C, BRON AM, BRETILLON L-Dijon

- 261 Butaprost, a prostaglandin EP2 receptor agonist, counteracts the negative effect of serum deprivation to retinal ganglion cells  
*rf*

KANG K, OSBORNE NN-Oxford

- 262 N-Acetyl cysteine (NAC) attenuates neuronal cell death in culture not solely by up regulating glutathione (GSH)

ABDUL MAJID AS, OSBORNE NN-Oxford

- 263 Ocular and plasma bioavailability of different memantine formulations after periocular administration

PRIETO CALVO E, BREGANTE UCEDO MA, PEREZ OLIVÁN S, PUENTE BAYO B-Zaragoza

- 264 Choroidal blood flow regulation during a latanoprost-induced decrease in intraocular pressure

BOLTZ A, FUCHSJAEGER-MAYRL G, LASTA M, PEMP B, SCHMIDL D, GARHOFER G, SCHMETTERER L-Vienna

- 265 Urocortin2 relaxes the iris sphincter muscle

ROCHA DE SOUSA A, TAVARES-SILVA M, FONSECA S, CARDOSO S, LEITE-MOREIRA AF-Porto

- 266 Choroidal blood flow response to hyperoxia and hypercapnia in patients with obstructive sleep apnea syndrome

KHAYI H, TONINI M, PEPEIN JL, RENARD E, BAGUET JP, ROMANET JP, GEISER MH, CHIQUET C-Grenoble, Sion

- 267 Intravitreal L-arginine injection reverses the retinal arteriolar vasoconstriction that occurs after experimental acute branch retinal vein occlusion

MENDRINOS E, PETROPOULOS IK, MANGIORIS G, PAPADOPOLOU DN, POURNARAS CJ-Geneva

- 268 The effect of betablockers on ocular hemodynamics in anesthetized rabbits

RUNGE CW, BOGNER B, STROHMAIER C, GRABNER G, REITSAMER HA-Salzburg

- 269 A rat model to study choroidal blood flow

STROHMAIER C, RUNGE CW, BOGNER B, GRABNER G, REITSAMER HA-Salzburg

- 270 Retrobulbar flow velocities in open angle glaucoma and their association with mean arterial blood pressure

KAYA S, FUCHSJAEGER-MAYRL G, RESCH H, GARHOFER G, PEMP B, VASS C, SCHMETTERER L-Vienna

- 271 Cis-urocanic acid suppresses UV-B-induced interleukin-6 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro

VIIRI J, JAUHONEN HM, RYHÄNEN T, PAIMELA T, SORRI I, LAIHIA JK, LEINO L, SALMINEN A, KAARNIRANTA K-Kuopio, Turku

- 272 Combined effects of aging and a pro-diabetic diet on retinal function in a murine model of aging of the human eye

SIMON E, ACAR N, BRON AM, CREUZOT C, BRETILLON L-Dijon

- 273 Efficacy and safety of topical cyclosporine versus vehicle in vernal keratoconjunctivitis in children

BREMOND-GIGNAC D, BERESNIAK A, CHIAMBARETTA F, AMRANE M, BAUDOUIN C-Amiens, Geneva, Clermont-Ferrand, Evry, Paris





**Friday**  
**October 2, 2009**



<b>Europa A</b>	<b>RV: Vitreoretinal surgery: from past to future</b>	08:15 – 09:45
FP	Philippe KOCH, Elisabeth VAN AKEN	
08:15	3111	Surgical experience and outcome of scleral buckling procedures in retinal detachment ARNDT C, FRANCERIE-SADDIKI V, BRUGNIART C, SEGAL A, DUCASSE A-Reims
08:27	3112	Investigation of particular surgical steps in epiretinal prostheses implantation procedure in pigs IVASTINOVIC D, GEORGIT, HORNIG R, WEDRICH A, VELIKAY-PAREL M-Graz, Bonn
08:39	3113	Sutureless encircling band – biomechanical calculations and clinical experience MAIER M, FEUCHT N, WINKLER VON MOHRENFELS C, KOTLIAR KE, LOHMANN CP-Munich
08:51	3114	Electronic subretinal implants allow blind retinitis pigmentosa patients to read letters and recognize the direction of fine stripe patterns ZRENNER E, WILKE R, BARTZ-SCHMIDT K, BENAV H, BESCH D, GEKELER F, KOCH J, PORUBSKA K, SACHS H, GREPPMAIER U, HARSCHER A, WILHELM B-Tübingen, Dresden, Reutlingen
09:03	3115	First experience with The IRIS retinal implant system VELIKAY-PAREL M, IVASTINOVIC D, LANGMANN G, HORNIG R, GEORGIT, WEDRICH A-Graz, Bonn
<b>Europa B</b>	<b>VEP: Colour vision</b>	08:15 – 09:45
FP	Bart LEROY, Werner SPILEERS	
08:15	3121	The study of chromatic and achromatic VEP in the first year of life TEKAVCIC POMPE M, STIRN KRANJC B, BRECELJ J-Ljubljana
08:27	3122	Acquired loss of chromatic sensitivity BARBUR J-London
08:39	3123	Differential effects of ageing on foveal and peripheral colour vision RAUSCHER F, EDGAR D, BARBUR J-London
08:51	3124	Chromatic sensitivity in subjects with diabetes O'NEILL-BIBA M, RODRIGUEZ-CARMONA M, RAUSCHER F, BARBUR J, SIVAPRASAD S-London
09:03	3125	Pre-receptoral spectral absorption, healthy ageing and pre-clinical indications of retinal disease KONSTANTAKOPOULOU E, BARBUR J-London
09:15	3126	On the effectiveness of cone mosaic geometry in sampling patterns near the Nyquist frequency GINIS H, PERDIKARIS K, PALLIKARIS A-Heraklion
<b>Emerald I</b>	<b>COS: Ocular surface and dry eye</b>	08:15 – 09:45
FP	Pierre Jean PISELLA, Philippe KESTELYN	
08:15	3131	Pterygium surgery long term follow-up WOOD T, WILLIAMS E, WILLIAMS B-Memphis, Atlanta
08:27	3132	Distribution of amyloid and BIG-H3 in the cornea and limbus of a patient with lattice corneal dystrophy. Unique findings in donated eyes AKHTAR S, ALMUBRAD T, BRON AJ, BONSHEK R-Riyadh, Oxford, Manchester
08:39	3133	Detection of osmoprotective effect of topical compatible solutes on ocular surface epithelia CALIENNO R, NUBILE M, LANZINI M, CURCIO C, COLESANTE M, CIAFRE M, MASTROPASQUA A-Chieti, Pescara
08:51	3134	Alcohol vs. mechanical delamination in the treatment of corneal erosion: an electron microscopic study PALADINI I, BRAHIMI B, MENCHINI U, DUA HS, ROMAGNOLI P, MENCUCCI R-Florence, Nottingham
09:03	3135 <i>rf</i>	Lymphocyte and markers of inflammation detection in the conjunctival epithelium of patients with dry eye by enhanced flow cytometry BARABINO S, MONTALDO E, SOLIGNANI F, MINGARI C, ROLANDO M-Genoa
09:09	3136 <i>rf</i>	Sutureless and glue free conjunctival autograft in pterygium surgery DE WIT DW, MOORE J-Cambridge, Belfast
09:15	3137 <i>rf</i>	Ocular surface findings in patients with congenital aniridia DE LA PAZ MF, BLANCO Z, ALVAREZ J-Barcelona
09:21	3138 <i>rf</i>	Compare optical with photometry measures of tear film lipid layer NEPP J, BENZ P, NELL B, SCHAUERSBERGER J-Vienna
09:27	3139 <i>rf</i>	Evaluation of spatial contrast sensitivity after the instillation of diclofenac eye drops KARAMPATAKIS V, CHATZIMPALIS T, KORDALI P, KALPATSANIDIS A, STAMOULAS K-Thessaloniki

<b>Emerald II</b>	<b>LC: Diabetic cataract: mechanisms and management</b>	08:15 – 09:45
SIS	Irina OBROSOVA, Peter KADOR	
08:15	3141	Loss of thioredoxin activity as an important contributor to oxidative stress in lens of diabetic rats LOU M, LECHNER J, XING K, KADOR PF-Lincoln, Omaha
08:37	3142	Treating diabetic dogs with topical Kinostat™ for cataracts: proof of concept clinical trial KADOR PF, ROBBIN-WEBB T, BRAS D, KETERING KL, WYMAN M-Omaha, Worthington, Columbus
08:59	3143	Anticataract effect as a predictor of drug efficacy against early diabetes-induced retinal changes OBROSOVA IG-Baton Rouge
09:21	3144	Differences in lens opacification in type 2 diabetic patients on oral anti-diabetic medication or insulin therapy WEGENER A, KREMER J, MÜLLER-BREITENKAMP R, LASER H-Bonn

<b>Mediterranea I</b>	<b>G: Glaucoma surgery</b>	08:15 – 09:45
FP	Ingeborg STALMANS, Alain BRON	
08:15	3151	Preoperative topical non-steroidal anti-inflammatory drug or steroid and clinical outcomes after trabeculectomy STALMANS I, SPIELBERG L, VANGINDERDEUREN R, ZEYEN T, BREUSEGEM C-Leuven
08:27	3152	Microplasmin improves surgical outcome in a rabbit model for trabeculectomy VANDEWALLE E, VAN BERGEN T, YOU Y, VAN DE VEIRE S, MOONS L, STALMANS I-Leuven
08:39	3153	Do patients with normal tension glaucoma have a thinner conjunctiva? VAN GINDERDEUREN R, STALMANS I, SPIELBERG L, ZEYEN T-Leuven
08:51	3154	Effect of phacoemulsification on the primary open angle glaucoma control after trabeculectomy: a case-control study AZIZ S, SPIRES N, JAY J-Leicester, Glasgow
09:03	3155	A new technique for diode laser cyclophotocoagulation: short term results SURIANO M, STIRBU O, VILA ARTEAGA J-Valencia
09:15	3156	Inflammation assessment after selective laser trabeculoplasty (SLT) treatment AYALA M, LANDAU HÖGBECK I, CHEN E-Stockholm

<b>Adria</b>	<b>NSPH: Jumping, jiggling and jerking eyes: recognition and management of unusual eye movement disorders</b>	08:15 – 09:45
SIS	Aki KAWASAKI, François-Xavier BORRUAT	
08:15	3161	Oculopalatal tremor BORRUAT FX-Lausanne
08:33	3162	Opsoclonus EGGENBERGER E-East Lansing
08:51	3163	Superior oblique myokymia KAWASAKI A-Lausanne
09:09	3164	Macrosquare wave jerks EGGENBERGER E-East Lansing
09:27	3165	Ocular neuromyotonia BOSCHI A-Bruxelles

**Keynote Lecture 2**  
10:00 – 10:45  
**Europa A**

**Age-related macular degeneration; an Alzheimer's disease in the eye?**  
Kyoko OHNO-MATSUI - Tokyo, Japan  
Introduction by Carl HERBORT



**European Professors of Ophthalmology**

# **EUPO COURSE 2010 • RETINA**

**October 1-3, 2010 • Athens, Greece**

**[www.eupo.eu](http://www.eupo.eu)**



**European Association for Vision and Eye Research**

# **EVER 2010**

**October 6-9, 2010**

**Crete** [www.ever.be](http://www.ever.be)

*Join EVER!*



**2011 > October 5-8, Crete**

**2012 > October 3-6, Crete**





## EBOD 2010 Examination

The European Board of Ophthalmology (EBO) Examination 2010 will take place on **May 7-8th, 2010** at the: **Palais des Congrès de Paris**, 2, Place Porte Maillot F-75017 PARIS FRANCE



**When?**  
May 7-8, 2010

**Where?**  
Paris, Palais des Congrès (Porte Maillot)

**Application period**  
From October 1, 2009 till January 31st 2010  
Electronic application form (website)

**More information...**  
<http://www.ebo-online.org>

Joint Congress of

# SOE AAO

4–7 June 2011  
Geneva  
Switzerland



For further information:  
[www.soe2011.org](http://www.soe2011.org)



European Society  
of Ophthalmology



**Europa A RV: Novelties in basic research in the vitreous**

11:00 – 12:30

SIS Elisabeth VAN AKEN, Marc D DE SMET



11:00	3211	Hereditary vitreoretinopathies SNEAD M-Cambridge
11:18	3212	Protein screening in vitreous samples of patients with retinal vein occlusion AGOSTINI HT, MARTIN G, HANSEN LL-Freiburg
11:36	3213	Pharmacokinetics of intraocular microplasmin. Revelance to the mechanism of action DE SMET M-Lauzanne
11:54	3214	Insights into the molecular basis of rhegmatogenous retinal detachment BISHOP PN-Manchester
12:12	3215	Transthyretin levels in the vitreous correlate with change in visual acuity after vitrectomy VAN AKEN E, VECKENEER M, DERYCKE L, DELANGHE J-Ghent, Rotterdam

**Europa B VEP: ISCEV Session**

11:00 – 12:30

Joint M. Colin BARBER, Pierre LACHAPELLE



11:00	3221	Target oriented selection of electrophysiological endpoints in preclinical and clinical trials ZRENNER E, WILHELM B, PETERS T, KURTENBACH A-Tübingen
11:18	3222	Separating physiological from pathological effects of drugs tested for retinal toxicity in animal models PERLMAN I-Haifa
11:36	3223	The mysterious a-wave LACHAPELLE P, GARON ML, POLOSA A, ZIMAK E-Montréal, Québec
11:54	3224	Electrophysiological assessment of optic neuropathies in neuro-ophthalmological practice HAWLINA M, BRECELJ J-Ljubljana
12:12	3225	Novel mutations and electrophysiological findings in RGS9 and R9AP associated retinal dysfunction (Bradyopsia). HOLDER GE, MICHAELIDES M, LI Z, RANA NA, RICHARDSON EC, HYKIN PG, MOORE AT, WEBSTER AR-London

**Emerald I COS: Anterior Segment Imaging**

11:00 – 12:30

SIS Jean-Jacques GICQUEL, Mario NUBILE

11:00	3231	Ultrasound biomicroscopy for the analysis of the anterior segment PEDROTTI E-Verona
11:15	3232	Anterior segment OCT in corneal diseases and surgery NUBILE M-Chieti
11:30	3233	In vivo confocal microscopy of the cornea and conjunctiva BAUDOUIN C-Boulogne Billancourt
11:45	3234	Diffuse keratoconjunctival diseases: an in vivo confocal microscopic study DUA HS-Nottingham
12:00	3235	Anterior segment OCT versus UBM in the surgical management of pseudophakic bullous keratopathy GICQUEL JJ-Poitiers
12:15	3236	Anterior segment OCT in glaucoma CIANCAGLINI M

<b>Emerald II</b>	<b>IC: Straylight in the human eye - Small versus large angle domain</b>	11:00 – 12:30
SIS	Ralph MICHAEL, Harilaos GINIS	
11:00	3241	The different domains of the point spread function - Small angle vs large angle VAN DEN BERG TJTP, COPPENS JE, FRANSSEN L-Amsterdam
11:15	3242	Challenges in optical measurement of scatter GINIS H-Heraklion
11:30	3243	Optical simulation of large and small angle scatterers DE BROUWERE D, GINIS H, PALLIKARIS IG-Galway, Heraklion
11:45	3244	Straylight in function of wavelength and refraction ROZEMA J, TASSIGNON MJ-Edegem
12:00	3245	Intraocular straylight screening in medical testing centres for driver licence holders in Spain MICHAEL R, VAN DEN BERG TJTP, BARRAQUER RI-Barcelona, Amsterdam
12:15	3246	Quality of life in cataract patients and the role of stray light ASPINAL P-Edinburgh

<b>Workshop</b>	<b>Women in ophthalmology: From bench to boardroom</b>
11:00 – 12:30	Adrienne Graves

<b>Mediterranea I</b>	<i>Introduction by Bahram BODAGHI</i>
-----------------------	---------------------------------------



Dr. Adrienne Graves began her career as a visual scientist, with stops at Brown University, Harvard Medical School, University of Michigan, and University of Paris. Her passion for studying the visual system and the pathophysiology of disease processes led her to the pharmaceutical industry. After positions in R&D at Alcon, she is now President/CEO of Santen's US operations. Dr. Graves credits her time in Paris for expanding her horizons in many ways, including an appreciation for cultural diversity. This is especially important in her role as a corporate officer of a global enterprise based in Japan.

<b>Adria</b>	<b>PO: Pathology-Oncology</b>	11:00 – 12:30
FP	Steffen HEEGAARD, Tero KIVELÄ	
11:00	3261	Oncocytic lesions of the ophthalmic region HEEGAARD S, ØSTERGAARD J, PRAUSE JU-Copenhagen, Roskilde
11:12	3262	A Western blot analysis of P-glycoprotein in retinoblastoma SETHI S, GHOSH S, PUSHKAR N, BAJAJ MS, KAUR J, KASHYAP S, MEHTA M, SAXENA P, CHAWLA B, CHANDRA M-Delhi
11:24	3263	Heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification (MLPA) DOPIERALA J, COUPLAND SE, DAMATO B-Liverpool
11:36	3264	Revisiting the value of assessing the mitotic rate of choroidal melanoma COUPLAND SE, DAMATO B-Liverpool
11:48	3265	Granular cell tumour of the lacrimal gland VON HOLSTEIN SL, ØSTERGAARD J, DAUGAARD S, TOFT PB, HEEGAARD S-Copenhagen, Roskilde
12:00	3266 <i>rf</i>	Immunohistochemical findings and proliferation markers in uveal melanomas after gamma knife radiosurgery WACKERNAGEL W, MAYER CF, LACKNER EM, SCHNEIDER MR, LANGMANN G, UNGER F, KLEINERT R-Graz
12:06	3267 <i>rf</i>	Ophthalmologic outcome of 40 spheno-orbital meningioma resections: 15 years long-term results NOCHEZ Y, FRANCOIS P, VELUT S, CARDON A, MAJZOUB S, JAN M, PISELLA PJ-Tours

12:35 – 13:35 **Business meetings of the scientific sections:**

**Sandwiches and refreshments**

**AGENDA**

1. Report of the chair of section
2. Report of the programme secretary
3. Next year's meeting:
  - nomination of a section programme secretary
  - proposals of Special Interest Symposia (SIS)
  - proposals for Keynote speakers
4. Comment on the EVER activities
5. Other business

- |  |                     |
|--|---------------------|
| - Anatomy / Cell Biology   | Hall Emerald I      |
| - Cornea / Ocular Surface  | Hall Emerald I      |
| - Glaucoma   | Hall Mediterranea I |
| - Immunology / Microbiology  | Hall Mediterranea I |
| - Lens and Cataract  | Hall Emerald II     |
| - Molecular Biology / Genetics / Epidemiology                              | Hall Emerald II     |
| - Neuro-ophthalmology / Strabismology / Paediatric ophthalmology / History | Hall Adria          |
| - Pathology / Oncology   | Hall Adria          |
| - Physiology / Biochemistry / Pharmacology                                 | Hall Europa B       |
| - Retina / Vitreous  | Hall Europa A       |
| - Vision Sciences/Electrophysiol./ Physiological Optics                    | Hall Europa B       |

In addition to the agenda, the sections **NSPH** and **PO** will nominate at least 2 candidates for section chair.

<b>Europa A</b>	<b>RV: Treatment of age-related macular degeneration</b>	13:45 – 15:15
FP	Catherine CREUZOT, Jean - Jacques DE LAEY	
13:45	3311	3 Intravitreal ranibizumab injections series for the treatment of neovascular age-related macular degeneration (AMD), 18 months follow-up GONZALEZ C-Toulouse
13:57	3312	Outcome of exudative aged-related macular degeneration (ARMD) after 3 intravitreal injections of bevacizumab CREUZOT C, BIDOT ML, SOUCHIER M, MALVITTE L, BRON AM-Dijon
14:09	3313	Combined intravitreal bevacizumab and triamcinolone for exudative age-related macular degeneration LIBONDI T, JONAS JB, GOLUPKINA L, SPANDAU UH, SCHLICHTENBREDE F, RENSCH F-Mannheim
14:21	3314	Focal photodynamic therapy for idiopathic polypoidal choroidal vasculopathy POPOSKY V, VILAPLANA D, ALARCON I, MARTINEZ-GIRALT O, POPOSKA D, CASTILLA M-Barcelona
14:33	3315	Prospective evaluation of macular and parapapillary morphology and their association with cognition in childhood and old age LAUDE A, HENDERSON RD, GOW AJ, DHILLON B, STARR JM, DEARY IJ-Edinburgh
14:45	3316 <i>rf</i>	Retinal angiomatic proliferation: is intravitreal ranibizumab therapy enough? MARJANOVIC B, GEORGODIS P, MANDAL K, PATRA S-Bristol
14:51	3317 <i>rf</i>	Combined 23-gauge sutureless pars plana vitrectomy (ppV), injection of recombined tissue plasminogen activator (rtPA), expansile gas and bevacizumab treating acute subretinal haemorrhage (SRH) in exudative AMD MAIER M, PERZ C, FEUCHTN, KONRAD J, WINKLER VON MOHRENFELS C, LOHMANN CP-Munich

<b>Europa B</b>	<b>VEP: Electrophysiology</b>	13:45 – 15:15
FP	Graham HOLDER, John BARBUR	
13:45	3321	Findings in electrooculography and multifocal electroretinography in patients after bevacizumab treatment for age-related macular degeneration MANKOWSKI W-Katowice
13:57	3322	Importance of electron microscopy in neuronal ceroid lipofuscinosis HALFELD FURTADO DE MENDONCA R, KOK F, ROSEMBERG S, YUKIHIKO TAKAHASHI W-São Paulo
14:09	3323	Extensive macular atrophy with pseudodrusen-like appearance (EMAP), a new clinical entity HAMEL C, MEUNIER I, ARNDT C, BEN SALAH S, LOPEZ S, BAZALGETTE C, ZANLONGHI X, ARNAUD B, DEFOORT-DELLHEMMES S, PUECH B-Montpellier, Reims, Nantes, Lille
14:21	3324	Accommodation and pupillary response in the reading of texts with varying cognitive demand MIHELCIC M-Aalen
14:33	3325	Prevalence of myopia in preschool Singapore Chinese children SAW SM, DIRANI M, GAZZARD G, MITCHELL P, VARMA R, WONG TY-Singapore, Melbourne, London, Sydney, Los Angeles
14:45	3326	Comparison of refractive cylinder and corneal cylinder in aphakic eyes PADRICK T, PACKER, MD, FACS M-Aliso Viejo, Eugene

<b>Emerald I</b>	<b>COS: Refractive surgery and anterior segment imaging cornea</b>	13:45 – 15:15
FP	Gilles THURET, Beatrice COCHENER	
13:45	3331	Central corneal thickness (CCT) and intraocular pressure (IOP) in myopic adult Chinese KACHANOV A, BALASHEVICH L, BAUER S, ZIMIN B, GOLOVATENKO S, TIEHUI Z, WANG X-St.-Petersburg, Daqing, Harbin
13:57	3332	Validation and use of simulated corneal endothelium specular microscopy images BUCHT C, SÖDERBERG PG, MANNEBERG G-Stockholm, Uppsala
14:09	3333	Intraocular pressure measurements values in patients who have had uneventful deep anterior lamellar keratoplasty DOMINIKA J, WYLEGALA E-Katowice
14:21	3334	Technical standardisation to measure the ocular surface lipid layer with Meibometer 550 NEPP J, BENZ P, SCHAUERSBERGER J, NELL B-Vienna
14:33	3335 <i>rf</i>	A pocket slitlamp ARMOUR R-Stevenage
14:39	3336 <i>rf</i>	Dextran 70 solutions for the intra-operative control of corneal hydration in rabbit corneas PENTARI I, GINIS H, DIAKONIS V, KYMIONIS G, PALLIKARIS IG-Heraklion
14:45	3337 <i>rf</i>	Simultaneous topo-guided photorefractive keratectomy (PRK) followed by collagen cross-linking (CXL) for the treatment of keratoconus KONTADAKIS GA, KYMIONIS G, PORTALIOU D, KOUNIS G, KARAVITAKI A, PALLIKARIS IG-Heraklion
14:51	3338 <i>rf</i>	Comparison of morphometric and morphological OCT Visante and UBM potential in anterior segment imaging MILKA M, WYLEGALA E-Katowice

<b>Emerald II LC: Lens</b>			13:45 – 15:15
FP	Jan-Olof KARLSSON, Alfred WEGENER		
13:45	3341	Antioxidants reduce diabetic damage in bovine lenses in culture DOVRAT A, BORMUSOV E, DOVRAT Y, CHEVION M–Haifa, Jerusalem	
13:57	3342	Cell death in lens epithelial cells after stimulation of the sigma-2 receptor KARLSSON JO, JONHEDE S, PETERSEN A, ZETTERBERG M–Gothenburg	
14:09	3343	Nanostructural properties of intraocular lenses (IOLs) – atomic force microscopy (AFM) and Fourier transform infrared spectroscopy (FTIR) investigations WYLEGALA E, MROZ I, JASTRZEBSKA M, WRZALIK R, MILKA M–Katowice, Wroclaw, Soanowiec	
14:21	3344	Predictive factors of visual outcome in acute post-cataract endophthalmitis COMBEY-DE LAMBERT A, THURET G, MAURIN M, BRON AM, CORNU PL, CREUZOT C, VANDENESCH F, DENIS P, ROMANET JP, CHIQUET C–Grenoble, St Etienne, Dijon, Lyon	
14:33	3345	The crystalline lens higher fatty acids influence on the lens physical characteristics KUDRYAVTSEVA Y, CHUPROV A–Kirov	
14:45	3346	Hardness of a crystalline lens and accommodation CHUPROV A, KUDRYAVTSEVA Y, KUDRYAVTSEV V–Kirov	

<b>Mediterranea I G: Glaucoma and disability</b>			13:45 – 15:15
SIS	Anna-Maria STEVENS, Thierry ZEYEN		
13:45	3351	Evaluation of quality of life, and priorities in people with glaucoma ASPINALL P–Edinburgh	
14:05	3352	Measuring visual disability in glaucoma KOTECHA A–London	
14:25	3353	What do patients with glaucoma do when they search and look at everyday scenes? SMITH ND, GARWAY-HEATH DF, CRABB DP–London	
14:45	3354	Fitness to drive in glaucoma patients- Preliminary study results STEVENS AM, LELOUP E, ZEYEN T–Gent, Leuven	
15:05		Panel discussion	

<b>Adria PO: The IC3D classification of corneal dystrophies and beyond</b>			13:45 – 15:15
SIS	Tero KIVELÄ, Hans Ulrik MØLLER		
13:45	3361	IC3D classification of corneal dystrophies MØLLER HU–Viborg	
14:00	3362	How to tell dystrophies of Bowman's layer (Reis-Bücklers and Thiel-Behnke) from one another KIVELÄ T–Helsinki	
14:15	3363	Overview of the TGFBI corneal dystrophies KLINTWORTH GK–Durham	
14:30	3364	A variant TGFBI corneal dystrophy from G623D mutation with an unusual amyloidogenic phenotype AGOSTINI HT, AUW-HÄDRICH C–Freiburg	
14:45	3365	TGFBI gene mutations in Hungary – polymorphic corneal amyloidosis caused by the novel F547S mutation BERTA A, LOSONCZY G, TAKACS L–Debrecen	

<b>Ophthalmic Research Lecture</b> 15:30 – 16:10 <b>Europa A</b>	<b>Role of the vascular endothelial cell in uveitis</b> Justine SMITH - Portland, USA Introduction by Uwe PLEYER	
--	--	---

<b>Poster session 2</b> 16:15 - 17:25 <b>Europa C</b> see pages 48-49	<b>Cornea/Ocular Surface - Lens/Cataract - Neuro-Ophthalmology - Pathology/Oncology - Vision Sciences/Electrophysiology/Physiological Optics</b> Jean-Jacques GICQUEL, Jan-Olof KARLSSON, Alfred WEGENER, Aki KAWASAKI, Jan PRAUSE, John BARBUR
--	--

<b>Europa A</b>	<b>RV: Progress in vitreo-retinal surgery: controversies in macular hole surgery</b>			17:30 – 19:00
SIS	Tina XIROU			
17:30	3411	New perspectives of optical coherence tomography in diagnosis and follow-up of macular holes KABANAROU SA, XIROU T, KOURENTIS C, KIDESS A, FERETIS E–Athens		
17:45	3412	Macular hole surgery with and without internal limiting membrane peeling KOURENTIS C, XIROU T, KABANAROU SA, KIDESS A, FERETIS E–Athens		
18:00	3413	Internal limiting membrane staining KATSIMPRIS J–Patras		
18:15	3414	23G versus 20G for macular hole surgery. Efficacy, safety and patient satisfaction PAPPAS G–Heraklion		
18:30	3415	Face down posturing for macular hole surgery. Is it really required? TRANOS P–Thessaloniki		
18:45	3416	Sulfur hexafluoride ( $SF_6$ ) versus perfluoropropane ( $C_3F_8$ ) gas tamponade for macular hole surgery STEFANIOTOU M–Ioannina		

<b>Europa B</b>	<b>VEP: Doctor, I see things that aren't there</b>			17:30 – 19:00
Workshop	Graham HOLDER			
17:30	3421	The initial consultation SPILEERS W–Leuven		
17:52	3422	Retinal causes LEROY BP–Ghent		
18:14	3423	Visual hallucinations and illusions: neurological considerations BORRUAT FX–Lausanne		
18:36	3424	Electrophysiology HOLDER GE–London		

<b>Emerald I</b>	<b>COS: Corneal endothelium: from biology to graft</b>			17:30 – 19:00
SIS	Gilles THURET			
17:30	3431	Predicted long-term outcome of corneal transplantation BORDERIE VM–Paris		
17:45	3432	Beyond penetrating keratoplasty: the challenge of endothelial transplantation BUSIN M–Forlì		
18:00	3433	Experimental assessment of endothelial viability of grafts THURET G, PIPPARELLI A–Saint-Etienne		
18:15	3434	Endothelial grafts with manually dissected endothelial-Descemet. Eye bank and surgical point of view MURAINÉ M–Rouen		
18:30	3435	Insights into regulation of the human corneal endothelial cell cycle JOYCE N–Boston		
18:45	3436	Developing gene therapies for corneal endothelial disorders LARKIN F–London		


<b>Emerald II</b>	<b>LC: Oxidation and cataract</b>	17:30 – 19:00
SIS	Stefan LÖFGREN, Marjorie F LOU	
17:30	Introduction by Marjorie Lou	
17:36	3441 Oxidative stress from in vivo dual waveband exposure to ultraviolet radiation SÖDERBERG PG, LI Y, GALICHANIN K, KRONSCHLÄGER M-Uppsala	
17:50	3442 Oxidative effects on the glutathione enzyme systems LÖFGREN S-Stockholm	
18:04	3443 The role of mitochondrial glutaredoxin-2 in protecting cells against oxidative stress LOU M, WU HL-Lincoln	
18:18	3444 Enhanced age-related and diabetes-induced cataract in mice lacking CuZn-superoxide dismutase OLOFSSON EM, MARKLUND SL, BEHNDIG A-Umeå	
18:32	3445 Orally active multi-functional antioxidants for the treatment of cataracts and AMD KADOR PF, RANDAZZO J, ZHANG P, BLESSING K-Omaha	
18:46	3446 The ubiquitin proteasome pathway - Repair or degradation of damaged proteins FERNANDES R, BENTO C, SEIÇA R, PEREIRA P-Coimbra	
<b>Mediterranea I</b>	<b>G: Trabeculectomy, the end of the surgery, but the beginning of the intervention</b>	17:30 – 19:00
SIS	Ingeborg STALMANS, Alain BRON, Thierry ZEYEN	
17:30	3451 We're still under pressure: postoperative hypertony STALMANS I-Leuven	
18:00	3452 Help, I've been too successful: postoperative hypotony ZEYEN T-Leuven	
18:30	3453 Cataract, loss of visual acuity, infection after trabeculectomy BRON AM-Dijon	
<b>Adria</b>	<b>IM: Gene therapy in ocular inflammation</b>	17:30 – 19:00
SIS	Philippe KOCH, Uwe PLEYER	
17:30	3461 Non-viral strategies of intra-ocular gene delivery BEHAR-COHEN F-Paris	
17:45	3462 Immune responses to gene therapy vectors in the context of corneal transplantation RITTER T, WILK M, GONG N, PLEYER U, NOSOV M-Galway, Berlin	
18:00	3463 Regulation of transgene expression KOCH P-Brussels	
18:15	3464 Gene therapy for corneal transplantation PLEYER U-Berlin	
18:30	3465 Gene therapy: can we prevent/modulate apoptosis in EC? FUCHSLUGER T, JURKUNAS U, KAZLAUSKAS A, DANA R-Boston	
18:45	3466 Gene therapy for posterior uveitis DICK AD-Bristol	





Europa A

<b>Ocular blood flow and glaucoma - an update</b>		19:00 – 20:00
Leopold SCHMETTERER		
19:00	Aging and glaucoma PILLUNAT L-Dresden	
19:18	AION and glaucoma: similarities and difference STALMANS I-Leuven	
19:36	Ocular blood flow and visual field preservation? MARTINEZ-GARCIA A-Santiago de Compostela	
20:00	End of session	



## Cornea/Ocular Surface

Moderator: Jean-Jacques GICQUEL, Philippe KESTELYN

- 301 Lymphocyte and markers of inflammation detection in the conjunctival epithelium of patients with dry eye by enhanced flow cytometry  
rf BARABINO S, MONTALDO E, SOLIGNANI F, MINGARI C, ROLANDO M–Genoa
- 302 Sutureless and glue free conjunctival autograft in pterygium surgery  
rf DE WIT DW, MOORE J–Cambridge, Belfast
- 303 Ocular surface findings in patients with congenital aniridia  
rf DE LA PAZ MF, BLANCO Z, ALVAREZ J–Barcelona
- 304 Compare optical with photometry measures of tear film lipid layer  
rf NEPP J, BENZ P, NELL B, SCHAUERSBERGER J–Vienna
- 305 Evaluation of spatial contrast sensitivity after the instillation of diclofenac eye drops  
rf KARAMPATAKIS V, CHATZIMPALIS T, KORDALI P, KALPATSANIDIS A, STAMOULAS K–Thessaloniki
- 306 A pocket slitlamp  
rf ARMOUR R–Steveage
- 307 Dextran 70 solutions for the intra-operative control of corneal hydration in rabbit corneas  
rf PENTARI I, GINIS H, DIAKONIS V, KYMIONIS G, PALLIKARIS IG–Heraklion
- 308 Simultaneous topo-guided photorefractive keratectomy (PRK) followed by collagen cross-linking (CXL) for the treatment of keratoconus  
rf KONTADAKIS GA, KYMIONIS G, PORTALIOU D, KOUNIS G, KARAVITAKI A, PALLIKARIS IG–Heraklion
- 309 Comparison of morphometric and morphological OCT Visante and UBM potential in anterior segment imaging  
rf MILKA M, WYLEGALA E–Katowice
- 310 Retinal detachments after Boston keratoprosthesis: incidence, predisposing factors and outcomes of repair  
rf JARDELEZA MS, DOHLMAN CH, YOUNG L–Boston
- 311 Prospective evaluation of the Boston keratoprosthesis  
rf AMENT JD, PINEDA R, TILAHUN Y, BEHLAU I, DOHLMAN CH–Boston, Addis Ababa
- 312 Cost-effectiveness of the Boston keratoprosthesis  
rf AMENT JD, STRYJEWSKI TP, DOHLMAN CH–Boston
- 313 Boston keratoprosthesis with titanium back plate  
rf DOHLMAN CH, TODANI A, AMENT JD, CHODOSH J, CIOLINO J, COLBY K, PINEDA R, BELIN M, AQUAVELLA J, GRANEY J–Boston, Albany
- 314 Comparison of deep anterior lamellar keratoplasty results in different TGF $\beta$ 1 corneal dystrophies  
rf NOWINSKA A, WYLEGALA E–Katowice
- 315 Comparison of the visual response to corneal enhancement on femtosecond and microkeratome created flaps  
CANADAS SUAREZ P, IBARZ-BARBERA M, HERNANDEZ -VERDEJO J, TEUS M–Madrid
- 316 Refractive and biomechanical results of intrastromal ring segments for keratoconus  
MICHAEL R, SANCHEZ C, MIKLEIEWICZ M, DE LA PAZ MF, ALVAREZ DE TOLEDO J, BARRAQUER RI–Barcelona
- 317 Descemet's membrane detachment diagnosis using a very high frequency ultrasound scanning system (Artemis 2, Ultralink LLC)  
STRATOS A, KYMIONIS G, BOUZOUKIS D, KROKIDIS M, TSILIMBARIS M, PALLIKARIS IG–Heraklion
- 318 Corneal waveform aberration measured by a rotary scanning system  
FRANCO S, OLIVEIRA C, ALMEIDA JB–Braga
- 319 Visual fields after refractive surgery  
DEMESTICHA A, GINIS H, KYMIONIS G, ASTIRAKAKIS N, PALLIKARIS IG–Heraklion
- 320 Optical qualities of the Boston keratoprosthesis  
SAYEGH RR, AVENA DIAZ L, VARGAS-MARTIN F, WEBB RH, DOHLMAN CH, PELI E–Boston
- 321 Reliability and interobserver variability of non-invasive tear film parameters  
KOSINA-HAGYO K, VERES A, FODOR E, LANG ZS, CSAKANY B, NEMETH J–Budapest

- 322 Ocular Response Analyzer waveforms analysis in normal and post-laser in situ keratomileusis eyes  
FRANCO S, FONSECA V, LIRA M–Braga

- 323 Wavefront analysis in unilateral herpetic keratitis  
KASWIN G, DE MONCHY I, POGORZALEK N, GENDRON G, OFFRET H, LABETOULLE M–Kremlin-Bicetre
- 324 Emergency keratoplasty  
VALYI Z, PEREZ GARCIA D, IBANEZ J, ROJO ARNAO M, MINGUEZ MURO E, CRISTOBAL JA–Zaragoza
- 325 Corneal biomechanics study: relationship between corneal aberration – hysteresis  
PEREZ GARCIA D, IBANEZ J, VALYI Z, CASAS P, CRISTOBAL JA–Zaragoza
- 326 Corneal biomechanics study (1): Central corneal thickness versus corneal resistance factor  
VALYI Z, IBANEZ J, PEREZ GARCIA D, JIMENEZ DEL RIO B, CRISTOBAL JA–Zaragoza
- 327 Tear level of nerve growth factor in normal dogs  
DODI PL, ZANOTTI C, ROSSI S, ALOE L–Parma, Forli, Rome
- 328 Histopathological aspects of complications of DSAEK: our experience  
PESCE G, VALENZANO E, MACINAGROSSA G, DI GESU I, MONTRONE F–Bari
- 329 Immune regulatory effect of rapamycin and cyclosporine A on experimental corneal allograft survival  
STANOJLOVIC S, SCHLICKEISER S, APPELT C, VOGT K, SCHMITT-KNOSALLA I, HAASE S, RITTER T, SAWITZKI B, PLEYER U–Berlin, Galway
- 330 Surveillance cultures of contact lenses of patients with Boston KPRO type keratoprosthesis  
DE LA CRUZ J, MCMAHON T–Chicago, Illinois
- 331 Effect of mitomycin C on the cicatricial corneal response on laser-assisted subepithelial keratectomy to correct myopia  
CANADAS SUAREZ P, GARCIA-GONZALEZ M, ARRANZ-MARQUEZ E, TEUS M–Madrid
- 332 Limbal choristomas – analysis of surgical technique and postoperative results (3 case reports)  
ASOKLIS R, BUTKENE L, JUODKAITE G, MAKSELIS A, PETROSKA D, PAJAUJIS M–Vilnius
- 333 Crosslinking by riboflavin and UVA. An electron transmission microscopy study in rabbits. Preliminary results  
MANGIORIS G, NATSIS K, NIKOLOUDIS A, PAPADOPOULOU DN, KOMNENOU A, KAROUTIS A, KARAMPATAKIS V–Thessaloniki
- 334 LASIK surgery for myopia in Chinese patients  
KACHANOV A, BALASHEVICH L, GOLOVATENKO S, TIEHUI Z, WANG X, BAUER S, ZIMIN B–St.-Petersburg, Daqing and Harbin
- 335 Photorefractive keratectomy FAREK in Chinese patients with myopia  
KACHANOV A, BALASHEVICH L, GOLOVATENKO S, TIEHUI Z, WANG X, BAUER S, ZIMIN B–St.-Petersburg, Daqing and Harbin, St.-Petersburg

## Lens/Cataract

Moderators: Jan-Olof KARLSSON, Alfred WEGENER

- 336 Impact on visual function from light scattering and glistenings in intraocular lenses  
MÖNSTAM E, BEHNDIG A–Umeå
- 337 Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell-death by reducing oxidative stress and stabilizing BAX/Bcl-2 ratio  
KERNIT M, HIRNEISS C, NEUBAUER AS, ULBIG MW, KAMPIK A–Munich
- 338 Protective effect of the thioltransferase gene on in vivo UVR-300 nm induced cataract  
KRONSCHLÄGER M, YU Z, GALICHANIN K, MEYER L, LÖFGREN S, SÖDERBERG PG–Uppsala, Stockholm, Bonn
- 339 Evaluation of the improvement of sensibility with the new IOL Master software version 5.4.3  
GALLEGO-PINAZO R, DIAZ-LLOPIS M, PARDO-LOPEZ D, LOPEZ-PRATS M, SANZ-MARCO E, LOPEZ-LIZCANO R, GARCIA-DELPECH S, UDAONDO-MIRETE P–Valencia
- 340 Aspheric intraocular lenses: effect of residual spherical aberration on objective quality of vision  
NOCHEZ Y, FAVARD A, MAJZOUB S, PISELLA PJ–Tours

## Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/History of Ophthalmology

Moderator: Aki KAWASAKI

- 341 Zone-I retinopathy of prematurity, progression and scheduling of treatment  
*rf*  
AKK尤N I, OTO S, YILMAZ G, TARCAN A, AKOVA AY-Ankara
- 342 Foveal serous detachment in juvenile idiopathic arthritis (JIA)-associated uveitis  
*rf*  
LIANG F, TERRADA C, DUCOS DE LAHITTE G, QUARTIER P, LEHOANG P, BODAGHI B-Paris
- 343 A bilateral congenital pits of the optic nerve head. A case report  
VILLAFRUELA I, CLARIANA A, RIVAS O, FERNANDEZ A, BORREGO R, COLAS T, ARTEAGA P, CACHO L-Madrid
- 344 Comparison of spectral-domain and time-domain optical coherence tomography for evaluation of macular thickness and peripapillary retinal nerve fiber layer in multiple sclerosis patients  
GARCIA MARTIN E, PUEYO V, PINILLA I, IDOPE M, GIL ARRIBAS L, FUERTES I, FERNANDEZ J-Zaragoza
- 345 Rehabilitative treatment of alexia  
VILLAFRUELA I, GANGOTRI L-Madrid
- 346 Superior oblique myokymia as a migraine motor aura  
KIRK A-Calgary, Alberta
- 347 Thyroid eye disease and the internet  
ZAIDI F, JONES C-Maidstone

## Pathology/Oncology

Moderator: Jan PRAUSE

- 348 Immunohistochemical findings and proliferation markers in uveal melanomas after gamma knife radiosurgery  
*rf*  
WACKERNAGEL W, MAYER CF, LACKNER EM, SCHNEIDER MR, LANGMANN G, UNGER F, KLEINERT R-Graz
- 349 Ophthalmologic outcome of 40 spheno-orbital meningioma resections: 15 years long-term results  
*rf*  
NOCHEZ Y, FRANCOIS P, VELUT S, CARDON A, MAJZOURB S, JAN M, PISELLA PJ-Tours
- 350 Uveal metastasis as initial manifestation of cancer  
NOVAK ANDREJCIC K, KRAUT A, TEKAVCIC POMPE M, JANCAR B-Ljubljana
- 351 IgG4-related sclerosing disease: Is there an association with orbital inflammatory pseudotumours?  
HERWIG MC, FISCHER HP, HOLZ FG, LOEFFLER KU-Bonn
- 352 Orbital and periorbital cystic lesions in Indian children: A retrospective analysis from a tertiary care hospital  
SETHI S, BAJAJ MS, PUSHKER N, MEHTA M, KASHYAP S, SEN S, CHAWLA B, GHOSE S-New Delhi
- 353 Serious retinal detachment caused by a choroidal metastasis treated with subtenon triamcinolone injection  
EGEA ESTOPINAN MC, PRIETO CALVO E, GUERRI MONCLUS N, RUIZ MORENO O-Zaragoza
- 354 Metastatic cancer presenting with ocular symptoms: a series of cases  
PEREZ GARCIA D, TOBENA PUYAL M, VALYI Z, IBANEZ J, ROJO ARNAO M, JIMENEZ DEL RIO B, CRISTOBAL JA, FERRER A-Zaragoza, Zaragoza
- 355 Comparison of mono- and bicanalicular silicone stent intubation in dacryocystorhinostomy  
BELTRAM M, PAJTLER A, DRNOVSEK-OLUP B-Ljubljana

## Vision Sciences/Electrophysiolog/ Physiological Optics

Moderator: John BARBUR

- 356 The effect of a yellow filter on visual performance of older subjects with low macular pigment optical density  
PUELL MC, BARRIO AR, PEREZ-CARRASCO MJ, PALOMO C-Madrid
- 357 Optical filters influence on pupil size according to their material and spectral characteristics  
SANCHEZ RAMOS C, VINAS-PENA M, PEREZ-CARRASCO MJ, GOMEZ-TORTUERO E, DIAZ-SERRANO Y, SILLERO-QUINTANA M-Madrid
- 358 Optico-anatomical changes of prematurity children eyes  
KRIAUCIUNIENE L, AUKESTIKALNIENE R, PAUNKSNIS A-Kaunas
- 359 How does normal crowding affect visual acuity?  
RAUSCHER F, HARLOW A, BARBUR J-London
- 360 Wavefront map analysis of single vision and progressive ophthalmic lenses  
PHILIPPAKI E, PLAINIS S, PALLIKARIS A, PAPADIAMANTIS A, PALLIKARIS IG-Heraklion
- 361 The effect of ocular higher order aberrations on contrast sensitivity  
GIANNAKOPOULOU T, PLAINIS S, PALLIKARIS A, PALLIKARIS IG-Heraklion
- 362 Validation of Modified Grating Test as a visual acuity test in low vision patients with retinitis pigmentosa  
GEORGI T, IVASTINOVIC D, HORNIG R, BRANDNER M, LANGMANN A, WEDRICH A, VELIKAY-PAREL M-Graz, Bonn
- 363 Anterior segment biometrics – investigation of hyperopic eyes with Orbscan  
JONUSCHEIT S, DOUGHTY MJ-Glasgow
- 364 The AGREE instrument applied to visual health: an assessment of the health protocols used in Spain to measure the effects exposure to VDT  
SEGUR CRESPO MM, LOPEZ NAVARRO A, RONDA PEREZ E, TASCON BERNABEU E, MARTINEZ VERDU FM-Alicante
- 365 Visual symptomatology associated with workers using VDT: a review in the last decade  
SEGUR CRESPO MM, LOPEZ NAVARRO A, RONDA PEREZ E-Alicante
- 366 Electroretinogram alterations in a monozygotic twin sisters discordant retinitis pigmentosa  
HALFELD FURTADO DE MENDONCA R, OLIVEIRA MAIA JUNIOR O, HENRIQUE NOVER G, YUKIHIKO TAKAHASHI W-Sao Paulo
- 367 The damaging effect of various intensities of light on retinal function in pigmented rats  
BARYLUK A, THALER S, REJDAK R, BOLZ S, ZRENNER E, ZARNOWSKI T-Tuebingen, Lublin
- 368 Analysis of multifocal electroretinography implicit times in the prediction of macular hole formation  
VARSANYI B, TUZSON R, NAGY BV, FERENCZ M, FARKAS A-Budapest
- 369 Morphofunctional changes of macular area in diabetic macular edema  
SHAMSHINOVA AM, MANSURINA NB, ARAKELYAN MA-Moscow
- 370 Development of a software for the exchange of electrophysiological data of vision with PACS systems based on DICOM  
STRASSER T, AVCU S, KONEV V, KORKMAZ F, MANAV E, SCHRECK T, TAU Kovic M, WILKE R, ZRENNER E-Tuebingen, Augsburg

Mark your calendar for the next  
EVER meeting in Crete  
October 6-9, 2010



**Saturday  
October 3, 2009**



**Europa A RV: Macular oedema: what is the best treatment?**

08:15 – 09:45

SIS Catherine CREUZOT



08:15	4111	Non surgical approach in diabetic macular edema: the future? CHIQUET C-Grenoble
08:33	4112	Which place for surgery for macular edema due to diabetic retinopathy? JONAS JB-Mannheim
08:51	4113	Is there still a place for vitrectomy in the treatment of macular edema due to venous occlusion ? POURNARAS CJ-Geneva
09:09	4114	Macular edema in epiretinal membrane and vitreomacular traction CREUZOT C-Dijon
09:27	4115	Macular edema and uveitis: may we find a place for surgery DE SMET M-Lauzanne

**Europa B KPro 1 session: design surgical techniques and complications**

08:15 – 09:45

Joint M. Claes DOHLMAN, Konrad HILLE, Paolo COLLIARDO



08:15		Welcome by Jean-Marie PAREL
08:20		Meeting rationale by Giancarlo FALCINELLI
08:25	4121	History of and necessity for KPros LIU C, GOMAA A-Brighton, Hove
08:35	4122	The first keratoprosthesis implantation in 1955 DE LA PAZ MF, BARRAQUER J-Barcelona
08:50	4123	Boston keratoprosthesis DOHLMAN CH-Boston
09:05	4124	Boston type I in pediatric patients AQUAVELLA J, CHAK G-Rochester
09:15	4125	Design, surgical technique and complications MOOKP FALCINELLI GC, COLLIARDO P-Rome
09:25	4126	AlphaCor, Pintucci, Supradescentemetic STOIBER J, HILLE K-Miami
09:35		Discussion

**Emerald I FRO: Belgian Fund for Research in Ophthalmology 1**

08:15 – 09:45

Joint M. Philippe KESTELYN, Marie - José TASSIGNON



08:15	4131	Gene transfer of disease regulated promoters during experimental autoimmune uveitis ELMALEH V-Brussels
08:30	4132	Evaluation of cerebrospinal fluid pressure in patients with Alzheimer's disease as a possible cause of glaucoma KIEKENS S, DE GROOT V, TASSIGNON MJ, DE DEYN PP-Antwerp
08:45	4133	Investigating the influence of wavelength, light intensity and macular pigmentation on retinal straylight ROZEMA J-Edegem
09:00	4134	The effect of microplamin on wound healing after glaucoma filtration surgery VAN BERGEN T-Leuven
09:15	4135	Study of the immune response in patients with uveitis and latent tuberculosis MAKHOUL D-Brussels
09:30		Questions / Discussion

<b>Emerald II</b>	<b>LC: The vision screen in the European mouse clinics</b>	08:15 – 09:45
SIS	Jochen GRAW	
08:15	4141	The Sanger Institute mouse genetics programme: progress on the high throughput characterisation of knockout mice GERDIN AK-Hinxton, Cambridgeshire
08:37	4142	Recent findings and perspectives of the vision screen in the German Mouse Clinic PUK O, FAVOR J, SUN M, DALKE C, GRAW J-Munich
08:59	4143	Screening for mouse eye and vision defects at MRC Harwell MULFORD C, JOYNSON R, CROSS S, WEST K, MCKIE L, JACKSON I-Edinburgh, Oxfordshire
09:21	4144	Visual phenotyping at the Institut Clinique de la Souris ROUX M, RIET F, MITTELHAEUSER C, MONTIAL M, LECOCQ M, MEZIANE H-Illkirch

<b>Mediterranea I</b>	<b>IM: EVER-SOIE: Progress in quantifying inflammation and monitoring uveitis</b>	08:15 – 09:45
Joint M.	Piergiorgio NERI, Ilknur TUGAL-TUTKUN	
08:15	4151	Precise monitoring of intraocular inflammation by LFP: the gold standard TUGAL-TUTKUN I-Istanbul
08:27	4152	Progress in monitoring inflammation in JIA BODAGHI B-Paris
08:39	4153	Gain in accuracy for diagnosis and follow-up of uveitis through indocyanine green angiography HERBORT CP-Lausanne
08:51	4154	Global angiographic scoring system for inflammatory diseases KHAIRALLAH M, TUGAL-TUTKUN I, HERBORT CP-Monastir, Istanbul, Lausanne
09:03	4155	Progress in monitoring inflammatory CMO DE SMET M-Lauzanne
09:15	4156	Progress in the appraisal and management of inflammatory CNVs NERI P-Ancona
09:27		Discussion

<b>Adria</b>	<b>OOG: Protocols 1</b>	08:15 – 09:45
Joint M.	Sarah COUPLAND	
08:15	4161	Metastatic disease in small uveal melanomas : retrospective review of 368 patients DEJARDINS L, LEVY GABRIEL C, LUMBROSO-LEROUIC L, DENDALE R, PLANCHER C, ASSELAIN B-Paris
08:25	4162	Clinical presentation, pathological features and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease VAN GINDERDEUREN R, CERBONE L, FIEUWS S, VAN EENO L, SPIEERS W, SCHOFFSKI P-Leuven
08:35	4163	Uveal melanoma: management and outcome of patients with extraocular spread CASSOUX N, BELLMANN C, LUMBROSO-LE ROUC L, LEVY-GABRIEL C, PLANCHER C, ASSELIN B, DENDALE R, DESJARDINS L-Paris
08:45	4164	Cytogenetic profile of locally invasive posterior uveal melanoma PARROZZANI R, ALEMANY-RUBIO E, PILOTTO E, URBAN F, BONALDI L, MIDENA E-Padova, La Habana
08:55	4165	Does delayed treatment shorten the life of patients with fatal choroidal melanoma? DAMATO B, COUPLAND SE-Liverpool
09:05	4166	An audit of eccentrically-positioned ruthenium plaque radiotherapy of choroidal melanoma in Liverpool RUSSO A, DAMATO B-Liverpool
09:15	4167	Primary photodynamic therapy of choroidal melanoma HEIMANN H, COUPLAND SE, DAMATO B-Liverpool
09:25	4168	Open-sky biopsy of ciliary body or choroidal tumors of undetermined origin: utility and safety SCHALENBOURG A, CHAMOT L, UFFER S, ZOGRAFOS L-Lausanne

<b>Keynote Lecture 3</b> 10:00 – 10:45 <b>Europa A</b>	<b>Unravelling the mysteries of ocular lymphomas</b> Sarah COUPLAND - Liverpool, UK Introduction by Steffen Heegaard	
--	--	---

<b>Europa A</b>	<b>RV: Diabetic retinopathy at a glance</b>	11:00 – 12:30
FP	Charles RIVA	
11:00	4211	Semi-automated assessment of microaneurysm formation rate from color fundus photographs in patients with mild NPDR BERNARDES R, NUNES S, PEREIRA I, LOBO C, CUNHA-VAZ J-Coimbra
11:12	4212	Validation of a predictive model for diabetic retinopathy progression in type-2 diabetic patients with mild nonproliferative diabetic retinopathy. NUNES S, BERNARDES R, LOBO C, CUNHA-VAZ J-Coimbra
11:24	4213	Retinal hemodynamic changes in diabetic macular edema HUDSON C, GUAN K, LAM WC, MANDELCORN M, DEVENYI RG, FLANAGAN JG-Toronto
11:36	4214 <i>rf</i>	Long-term result of intravitreal steroid for macular oedema: 2 to 5 year follow-up of 92 eyes ZAIDI F, ANSARI E-Maidstone
11:42	4215 <i>rf</i>	The relationship between retinal hemodynamics and systemic markers of endothelial function and Inflammation in type 2 diabetes HUDSON C, KHUU LA, PALKA E, FLANAGAN JG, WONG T, LAM WC, MARKOWITZ SN, BRENT M, MANDELCORN M, DEVENYI RG-Toronto
11:48	4216 <i>rf</i>	Assessment of retinal arteriolar hemodynamics in patients pre- and post-cataract extraction HUDSON C, AZIZI B, WAN J, WONG T, SINGER S-Toronto, Waterloo
11:54	4217 <i>rf</i>	Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy MUQIT MMK, GHANCHI FD, WAKELY L, HENSON DB, STANGA PE-Manchester, Bradford
<b>Europa B</b>	<b>KPro 2 session: Clinical results and indications</b>	11:00 – 12:30
Joint M.	Günther GRABNER, Giancarlo FALCINELLI, James AQUAVELLA	
 KPro Study Group		
11:00	4221	How should we quantify the performance of KPro's? VATI GRABNER G, STOIBER J, HITZL W-Salzburg
11:10	4222	The Boston keratoprosthesis in autoimmune disease CHODOSH J-Boston
11:22	4223	Boston keratoprosthesis in pediatric patients AQUAVELLA J
11:32	4224	Long-term functional and anatomical results of OOKP and tibial OKP: Barcelona experience DE LA PAZ MF, BARRAQUER J-Barcelona
11:42	4225	Tibial KPro TEMPRANO J-Barcelona
11:50	4226	MOOKP clinical results and Indications FALCINELLI G-Rome
12:00	4227	AlphaCor, Pintucci, Supradescentetic PROSDOCIMO G-Conegliano
12:10	4228	Clinical decision paths in KPro Surgery GRABNER G, STOIBER J, HITZL W-Salzburg
12:20		Discussion
<b>Emerald I</b>	<b>FRO: Belgian Fund for Research in Ophthalmology 2</b>	11:00 – 12:30
Joint M.	Philippe KESTELYN, Marie - José TASSIGNON	
 FRO		
11:00	4231	Safety evaluation of intravitreal use of a beta2-agonist in rabbit eyes VAN CALSTER J, VERSTRAETEN S, STALMANS P-Leuven
11:15	4232	The role of lox and LOXL2 in inflammation and fibrosis in a laser induced mouse model VAN DE VEIRE S-Leuven
11:30	4233	Can preoperative bevacizumab improve trabeculectomy outcome? Avastin-Trab study VANDEWALLE E-Leuven
11:45	4234	Is neuroglobin (Ngb) a perspective for glaucoma? YOU Y-Leuven
12:00	4235	Immunimodulation of corneal epithelial cells following electroporation with mRNA encoding IL-10 and FasL ZAKARIA N-Antwerp
12:15		Questions / Discussion

<b>Emerald II</b>	<b>LC: Microincision cataract surgery (MICS), is smaller better?</b>	11:00 – 12:30
SIS	Alain BRON	



11:00	4241	Fundamentals of cataract development WEGENER A-Bonn
11:18	4242	Micro-incision (MICS), perfecting wound incision COCHENER B-Brest
11:36	4243	MICS, mastering the critical steps BELLUCCI R
11:54	4244	MICS and vitreo retinal surgeries CREUZOT C-Dijon
12:12	4245	MICS and glaucoma BRON AM-Dijon

<b>Mediteranea I</b>	<b>IM: Anti-infectives: from research to clinic</b>	11:00 – 12:30
SIS	Regis KOWALSKI, Eric ROMANOWSKI	
11:00	4251	Prophylaxis of posttraumatic endophthalmitis ABU EL ASRAR A-Riyadh
11:18	4252	Animal studies for the prevention of endophthalmitis KOWALSKI RP-Pittsburgh
11:36	4253	Bacterial keratitis: the clinical problem PLEYER U-Berlin
11:54	4254	Animal models for the treatment of bacterial keratitis KOWALSKI RP-Pittsburgh
12:12	4255	The use of animal models for the evaluation of ocular antiviral agents ROMANOWSKI EG-Pittsburgh

<b>Adria</b>	<b>PO: Radiotherapy in ophthalmic oncology</b>	11:00 – 12:30
SIS	Laurence DESJARDINS, Bertil DAMATO	
		supported by
11:00	4261	Basic principles of radiotherapy in ophthalmic oncology DENDALE R, FOURNIER - BIDOZ N, CAMPITELLI M, CALUGARU V, LUMBROSO - LE ROUC L, LEVY C, PIERRAT N, MAZAL A, DESJARDINS L, FOURQUET A-Paris
11:15	4262	The treatment of uveal melanoma by ruthenium plaques DAMATO B-Liverpool
11:30	4263	18 years experience of the use of proton beam in ophthalmic tumours DESJARDINS L, LUMBROSO-LE ROUC L, LEVY C, PLANCHER C, ASSELAIN B, DELACROIX S, DENDALE R-Paris, Orsay
11:45	4264	Limiting the sequelae of irradiation in retinoblastoma patients by using globe and orbital brachytherapy with iodine 125 STANNARD C
12:00	4265	The use of ruthenium plaque brachytherapy in retinoblastoma ABOUZEID H, MOECKLI R, GAILLARD MC, BECK-POPOVIC M, PICCA A, ZOGRAFOS L, BALMER A, PAMPALLONA S, MUNIER F-Lausanne, Evolène
12:15	4266	The treatment of uveal melanoma with iodine plaque brachytherapy KIVELÄ T-Helsinki





Europa A

<b>Role of Inflammation in RVO</b>		12:35 – 13:35
Gisèle SOUBRANE, Constantin POURNARAS		
12:35	Macular edema and RVO. Role of inflammation POURNARAS CJ–Geneva	
12:50	Use of steroids in Macular Edema, are all the steroids the same? DE SMET M–Lausanne	
13:05	New developments in treating Macular Edema, Posurdex RVO Phase III results SOUBRANE S–Créteil	
13:20	Macular edema – With all the new data (BRAVO, SCORE and Posurdex) where to from here? DE SMET M–Lausanne	
13:35	End of session	

**Europa A RV: New ocular imaging in retinopathies**

13:45 – 15:15

SIS Gisèle SOUBRANE

13:45	4311	Principle of adaptive optics SÖDERBERG PG–Uppsala
14:00	4312	Telangiectasia evaluated with adaptive optics and HR-OCT ATMANI K, LEVEZIEL N, SOUBRANE G–Creteil
14:15	4313	Spectral domain OCT of exudative AMD LEVEZIEL N, VOIGT M, COSCAS G, SOUBRANE G–Creteil
14:30	4314	Drusen in adaptive optics and SD-OCT MASSAMBA N, LAMORY B, SOUBRANE G–Creteil, Orsay
14:45	4315	Chorioretinal anastomosis in adaptive optic and high definition spectral domain optical coherence tomography MAILLON C, VOIGT M, COSCAS G, SOUBRANE G–Creteil
15:00	4316	Perspective for adaptive optics CHATEAU N, LAMORY B–Orsay

**Europa B KPro 3 session**

13:45 – 15:15

Joint M. Joaquin BARRAQUER, Giancarlo FALCINELLI, Jean Marie PAREL



13:45	4321	Running a clinical service for KPros BARATZ K
13:55	4322	How do we get started with offering MOOKP clinical service? FUKUDA M, HAMADA S, LIU C–Osaka, Brighton
14:05	4323	Why we never use a KPro and MOOKP KINOSHITA SS–Kyoto
14:15	4324	Inflammatory responses to KPro: can we control them? PEREZ VS–Miami
14:25	4325	Retinal detachment in Falcinelli's modified osteodontokeratoprosthesis COLLIARDO P, FALCINELLI G–Rome
14:35	4326	Tibial Bone KPro technique and long term results TEMPRANO J–Barcelona
14:45	4327	Management of oculoplastic problems in the OOKP eye GOMAA A, MORRIS S, BRITTAINE P, HEROLD J, THORP S, LIU C–Brighton
14:55	4328	Dealing with complications of MOOKP: VR HUGHES E–Bristol
15:05		Discussion

**Emerald I ACB: Cell biology of the retina**

13:45 – 15:15

FP Richard BRUENECH, Kai KAARNIRANTA

13:45	4331	Quantification of neuronal cells in healthy rat retinas by flow cytometry TSOKA P, PAPADAKI E, PALLIKARIS IG, TSILIMBARIS M–Heraklion
13:57	4332	Clearance of dying cells in the retina - relevance to age-related macula degeneration PETROVSKI G, BERENYI E, VAJAS A, FESUS L, FACSKO A, BERTA A–Debrecen
14:09	4333	Role of HSP70 and p62 in regulation of autophagy clearance in ARPE-19 cells KAARNIRANTA K–Kuopio
14:21	4334	Occludin changes in retinal vessels after experimental vein thrombosis in rats TSILIMBARIS M, TSOKA P, BOCHATON-PIALLAT ML, CHRISTODOULAKIS E, GILODI N, POURNARAS CJ–Heraklion, Geneva
14:33	4335	Structural consequences after intravitreal bevacizumab injection in a retinopathy of prematurity mouse model AKKOUN I, YILMAZ G, OTO S, KARABAY G, HABERAL N, ERKANLI L, BACANLI D, AKOVA A Y–Ankara
14:45	4336	Relationship between VEGF expression and the retina following light-damage CACHAFEIRO M, BEMELMANS AP, WENZEL A, ARSENIEVIC Y–Lausanne, Zurich

**Poster session 3**

15:20 - 16:30

**Europa C**

see pages 62-63

**Immunology/Microbiology - Retina/Vitreous**Friederike MACKENSEN, François WILLERMAIN, Constantin POURNARAS, Charles RIVA  
Posters on pages 60-61

<b>Emerald II</b>	<b>ARVO Session: Finding a US Postdoctoral Fellow Position</b>	13:45 – 15:15
Joint M.	Sally ATHERTON	
Essential for anyone considering a US fellowship.		
<p>Helpful advice on finding the best location, mentor and financial arrangements for a rewarding experience will be presented. Lore Anne McNichol, PhD, Deputy Director of the National Eye Institute, will discuss how to apply for an NIH/NEI postdoctoral position. Sally Atherton, PhD of the Medical College of Georgia, will cover the opportunities in universities and what is needed regarding visas and how to make the system provide the experience that you want. Marzena Gajecka, PhD of the Polish Academy of Sciences will speak about her experience at Washington State University. Ample time for questions and answers.</p>		

<b>Mediterranea I</b>	<b>IM: Trends in ocular immunology and microbiology research</b>	13:45 – 15:15
FP	Philippe KOCH, Regis KOWALSKI	
13:45	4351	Circulating bone marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes ABU EL ASRAR A, STRUYF S, VERBEKE H, VAN DAMME J, GEBOES K-Riyadh, Leuven
13:57	4352	Encouraging results of a VEGF antibody against experimental choroidal neovascularization ABITBOL B, PROVOST A, GROUARD-VOGEL G, BERNIER S, ADAM-BUCZKOWSKI E, ZAGURY D, ABITBOL M-Paris
14:09	4353	Experience with adalimumab for the treatment of non-infectious uveitis DOBNER B-Heidelberg
14:21	4354	Ocular toxoplasmosis recurrences: a single center case report SERRA U, JULIAN K, AKNIN C, CASSOUX N, FARDEAU C, BODAGHI B-Pavia, Paris
14:33	4355	Ophthalmic microsporidiosis: the Manchester experience BONSHEK R, CURRY A, IRION L-Manchester
14:45	4356 <i>rf</i>	Topical levofloxacin 1.5% is effective in reducing levofloxacin-resistant MRSA and FQ-resistant pseudomonas aeruginosa in keratitis models KOWALSKI RP, ROMANOWSKI EG, MAH FS, SHANKS RMQ, GORDON YJ-Pittsburgh
14:51	4357 <i>rf</i>	TNF $\alpha$ suppresses IFN $\gamma$ -induced MHC Class II expression in retinal pigmented epithelial cells by down regulating Class II trans-activator mRNA MAKHOUL M, BRUYNS C, KOCH P, CASPERS L, WILLERMAIN F-Bruxelles
14:57	4358 <i>rf</i>	In vitro antimicrobial effect of vitreous endotamponading substances MONTERO MORENO JA, SANCHIS MERINO ME, RUIZ-MORENO JM-Valladolid, Albacete
15:03	4359 <i>rf</i>	An epidemiologic analysis of staphylococcus aureus-associated keratitis in Boston BEHLAU I, HEIMER SR, LEONARD EM, MARTIN JN, DOHLMAN CH, GILMORE MS-Boston
15:09	435a <i>rf</i>	Comparative assessment of S. aureus microbial biofilm inhibition by an N-alkyl-polyethyleneimine covalently attached to PMMA or titanium in the Boston Keratoprosthesis BEHLAU I, MUKHERJEE K, TODANI A, KLIBANOV AM, GILMORE MS, DOHLMAN CH-Boston, Cambridge

<b>Adria</b>	<b>OOG: Protocols 2</b>	13:45 – 15:15																								
Joint M.	Sarah COUPLAND																									
																										
<table border="1"> <tr> <td>13:45</td> <td>4361</td> <td>Pigmented eyelid lesion - unexpected findings LOEFFLER KU-Bonn</td> </tr> <tr> <td>13:55</td> <td>4362</td> <td>Uveal melanoma in a 12-year old child DESJARDINS L, LEVY-GABRIEL C, SASTRE X, MICHON J-Paris</td> </tr> <tr> <td>14:05</td> <td>4363</td> <td>Irido-cilio-choroidal melanoma in a 5-year old child PE'ER J-Jerusalem</td> </tr> <tr> <td>14:15</td> <td>4364</td> <td>A child with a melanocytic ciliary body tumour KIVELÄ T-Helsinki</td> </tr> <tr> <td>14:25</td> <td>4365</td> <td>Local resection of end-stage choroidal melanoma DAMATO B-Liverpool</td> </tr> <tr> <td>14:35</td> <td>4366</td> <td>Large retinal hemangioma treated in second hand by betabronchotherapy, on a single eye of a young adult GRANGE JD, KODJIKIAN L-Lyon</td> </tr> <tr> <td>14:45</td> <td>4367</td> <td>Sudden loss of vision 15 years after renal transplantation COUPLAND SE, THUMANN G-Liverpool</td> </tr> <tr> <td>14:55</td> <td>4368</td> <td>Orbital mantle cell lymphoma BRISCOE D-Kfar Saba</td> </tr> </table>			13:45	4361	Pigmented eyelid lesion - unexpected findings LOEFFLER KU-Bonn	13:55	4362	Uveal melanoma in a 12-year old child DESJARDINS L, LEVY-GABRIEL C, SASTRE X, MICHON J-Paris	14:05	4363	Irido-cilio-choroidal melanoma in a 5-year old child PE'ER J-Jerusalem	14:15	4364	A child with a melanocytic ciliary body tumour KIVELÄ T-Helsinki	14:25	4365	Local resection of end-stage choroidal melanoma DAMATO B-Liverpool	14:35	4366	Large retinal hemangioma treated in second hand by betabronchotherapy, on a single eye of a young adult GRANGE JD, KODJIKIAN L-Lyon	14:45	4367	Sudden loss of vision 15 years after renal transplantation COUPLAND SE, THUMANN G-Liverpool	14:55	4368	Orbital mantle cell lymphoma BRISCOE D-Kfar Saba
13:45	4361	Pigmented eyelid lesion - unexpected findings LOEFFLER KU-Bonn																								
13:55	4362	Uveal melanoma in a 12-year old child DESJARDINS L, LEVY-GABRIEL C, SASTRE X, MICHON J-Paris																								
14:05	4363	Irido-cilio-choroidal melanoma in a 5-year old child PE'ER J-Jerusalem																								
14:15	4364	A child with a melanocytic ciliary body tumour KIVELÄ T-Helsinki																								
14:25	4365	Local resection of end-stage choroidal melanoma DAMATO B-Liverpool																								
14:35	4366	Large retinal hemangioma treated in second hand by betabronchotherapy, on a single eye of a young adult GRANGE JD, KODJIKIAN L-Lyon																								
14:45	4367	Sudden loss of vision 15 years after renal transplantation COUPLAND SE, THUMANN G-Liverpool																								
14:55	4368	Orbital mantle cell lymphoma BRISCOE D-Kfar Saba																								

**Europa A EVER General Assembly and Prize Giving**

16:40 – 17:40

**Agenda**

1. President's address
2. Minutes of the General Assembly 2008
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, approval of the accounts 2008, discharge to the directors, budget for 2009
6. Results of the elections
7. Announcement of the replacement of the Chair of the Pathology/Oncology Section
8. Acta Board members
9. Presentation of the board 2009-2010
10. President Elect, Vice President Elect
11. Presentation and Report of the Scientific Sections meetings
12. Future congresses
13. Prize giving
14. Miscellanea

**Europa A RV: Choroidal blood flow in the healthy and diseased eye**

17:45 – 19:15

SIS Benedetto FALSINI, Christophe CHIQUET

17:45	4411	Complex regulation of choroidal blood flow during combined changes in blood pressure and IOP SCHMETTERER L-Vienna
18:00	4412	Evaluation of choroidal blood flow after treatment of retinal diseases CHIQUET C, GEISER MH-Grenoble, Sion
18:15	4413	Age-related macular degeneration: hemodynamic changes POURNARAS CJ, POURNARAS JAC, MENDRINOS E-Geneva, Lausanne
18:30	4414	Subfoveal choroidal blood flow and central retinal function in retinitis pigmentosa FALSINI B-Rome
18:45	4415	Autoregulation in the choroid ORGUL S-Basel
19:00	4416	Choroidal blood flow and retinal ganglion cell function in early glaucoma MARANGONI D, COLOTTO A, SALGARELLO T, STIFANO G, PARISI V, RIVA CE, CAMPOS EC, FALSINI B-Rome, Bologna

**Europa B KPro 4 session**

17:45 – 19:15

Joint M. Christopher LIU, Masahiko FUKUDA, M TALONI



17:45	4421	Biosynthetic corneas – evaluation in humans FAGERHOLM P, LAGALI N, GRIFFITH M-Linköping, Ontario
17:55	4422	Keratoprosthesis surgery: Eastern European and Russian devices ZAGORSKI ZF, YAKIMIENKO S, MOROZ ZI-Lublin, Odessa, Moscow
18:05	4423	Glaucoma associated with KPros HILLE K-Offenburg
18:15	4424	Improving the optics of KPros HULL C, GOMAA A, LIU C-London, Brighton
18:33	4425	Glaucoma treatment in MOOKP TALONI M, FALCINELLI G
18:41	4426	An antibiotic releasing contact lens CIOLINO J, HOARE T, IWATA N, BEHLAU I, DOHLMAN CH, LANGER R, KOHANE D-Boston, Cambridge
18:49	4427	Does imaging help with preventing extrusion? GOMAA A, SIPKOVA Z, FRANCIS I, HEROLD J, THORP S, LIU C-Brighton
18:57	4428	The clinical psychologist's role in the OOKP clinic. A one year review BUSUTTIL A, HOIT C, CAMIC P, GOMAA A, HEROLD J, THORP S, LIU C-Brighton
19:05		Discussion

**Emerald I IM: How to get your work published ?**

17:45 – 19:15

Workshop Uwe PLEYER

Junior researchers often face the challenge of getting their interesting work published. The goal of this course will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article. The panelists will discuss major aspects of the editorial process including basic decisions: where to submit the work, how to organize and prepare a manuscript, how to deal the review process in particular the revision process for eventual resubmission.

The panelists will raise the discussion on issues like:

- How to choose a journal ?
- How to organize your paper ?
- What are the characteristics of a good manuscript ?
- Delayed response: When is it appropriate to ask for the status of your manuscript ?
- How to interpret the letter from the editor ?
- How to write a good reply to the reviewers ?
- What to do when your paper is rejected ?
- When can it be appropriate to request a reevaluation of a rejected paper ?

In addition, the personal view from an authors and editors perspective will be given in a vivid discussion with the participants.

Panel: Pinar Aydin, Harminder Dua, Jochen Graw, Uwe Pleyer

**Mediterranea I IM: Ocular inflammation and infection: new agents and newly recognised inflammatory disease patterns**

17:45 – 19:15

SIS Moncef KHAIRALLAH, Carl P HERBORT

supported by 

17:45	4451	Introduction by Carl HERBORT
18:00	4452	Emerging and poorly known viral inflammatory eye diseases KHAIRALLAH M-Monastir
18:15	4453	Uveitis caused by fastidious bacteria BODAGHI B, DRANCOURT M, CASSOUX N, RAOULT D, LEHOANG P-Marseille, Paris
18:30	4454	Serpiginous choroiditis revisited MACKENSEN F-Heidelberg
18:45	4455	Appraisal and management of subclinical choroidal inflammation: the iceberg phenomenon HERBORT CP-Lausanne
19:00	4456	Significance of autofluorescence in choriocapillaritis MANTOVANI A, HERBORT CP-Como, Lausanne

**Adria OOG: Business Meeting**

17:45 – 19:15

Joint M. Sarah COUPLAND

1. Matters arising from the Minutes
2. Nominations for OOG Membership
3. OOG Website update
4. Trial Proposals and Updates:
  - Tero Kivila: Intravitreal salvage chemotherapy for retinoblastoma after chemoreduction
  - Bertil Damato: Non-treatment of uveal melanomas – new proposal
  - Bertil Damato: Update on conjunctival melanoma study
  - Martine Jager: TORR update
5. Any Other Business (AOB):
6. Future Meeting details:
  - Liverpool/Wales – March 19th-21st, 2010
  - EVER/OOG - Crete Oct 6-9, 2010

**Social**20:00 - 23:00  
in S. Bernardin

EVER Farewell dinner with musical entertainment



## Immunology/Microbiology

Moderators: Friederike MACKENSEN, François WILLERMAIN

- 401 **Topical levofloxacin 1.5% is effective in reducing levofloxacin-resistant MRSA and FQ-resistant pseudomonas aeruginosa in keratitis models**  
KOWALSKI RP, ROMANOWSKI EG, MAH FS, SHANKS RMQ, GORDON YJ-Pittsburgh
- 402 **TNF $\alpha$  suppresses IFN $\gamma$ -induced MHC Class II expression in retinal pigmented epithelial cells by down regulating Class II trans-activator mRNA**  
MAKHOUL M, BRUYN S, KOCH P, CASPERS L, WILLERMAIN F-Bрюссель
- 403 **In vitro antimicrobial effect of vitreous endotamponading substances**  
MONTERO MORENO JA, SANCHIS MERINO ME, RUIZ-MORENO JM-Valladolid, Albacete
- 404 **An epidemiologic analysis of Staphylococcus aureus-associated keratitis in Boston**  
BEHLAU I, HEIMER SR, LEONARD EM, MARTIN JN, DOHLMAN CH, GILMORE MS-Boston
- 405 **Comparative assessment of S. aureus microbial biofilm inhibition by an N-alkyl-polyethyleneimine covalently attached to PMMA or titanium in the Boston keratoprosthesis**  
BEHLAU I, MUKHERJEE K, TODANI A, KLIBANOV AM, GILMORE MS, DOHLMAN CH-Boston, Cambridge
- 406 **Three years experience of Quantiferon® Gold testing**  
JAKOB E, MACKENSEN F, BECKER MD, MAX R, DALPKA A, ZIMMERMANN S-Heidelberg, Zürich
- 407 **Implantation of intraocular lens in children with uveitis: long term visual outcome and prognosis**  
HAY A, TERRADA C, AKNIN C, CASSOUX N, LE HOANG P, BODAGHI B-Paris
- 408 **Aqueous humor heparin-binding epidermal growth factor-like levels in patients with acute anterior uveitis.**  
FRANCES-MUNOZ E, GALLEGOS-PINAZO R, DIAZ-LLOPIS M, SALOM D, GARCIA-DELPECH S, UDAONDO-MIRETE P, SANZ E-Valencia
- 409 **Aqueous humor keratinocyte growth factor levels in patients with acute anterior uveitis**  
FRANCES-MUNOZ E, GALLEGOS-PINAZO R, DIAZ-LLOPIS M, GARCIA-DELPECH S, SALOM D, UDAONDO-MIRETE P, MARIN-LAMBIES C-Valencia
- 410 **A case of intraocular dirofilaria in a dog: alarm bell for human beings?**  
DODI PL, ZANOTTI C-Parma, Forlì
- 411 **Inhibition of viral replication in vitro by antiviral-treated amniotic membrane**  
MENCUCCI R, PALADINI I, MENCHINI U, DEI R-Florence
- 412 **Ultrastructure of anterior lens capsule in uveitic cataract**  
STUNF S, HVALA A, VIDOVIC VALENTINCIC N, KRAUT A, HAWLINA M-Ljubljana
- 413 **Wiskott-Aldrich syndrome: A case with scleritis**  
KARAMPATAKIS V, HATZISTILIANOU M, KORDALI P, BISMPAS I-Thessaloniki
- 414 **The role of VEGF in intermediate uveitis patients**  
VIDOVIC VALENTINCIC N, KRAUT A, KOROSEC P, HAWLINA M, ROTHova A-Ljubljana, Golnik, Utrecht
- 415 **Intracameral amphotericin B in the management of Candida glabrata anterior uveitis after penetrating keratoplasty**  
SCHOLLMAYER P, KRAUT A, GLOBOCNIK-PETROVIC M, PFEIFER V-Ljubljana
- 416 **Diffusion tensor magnetic resonance imaging and fiber tracking of trigeminal nerves in relapsing herpetic keratouveitis**  
LABETOULLE M, NASSER G, DE MONCHY I, GENDRON G, OFFRET H, DUCREUX D, BENOUDIBA F-Kremlin-Bicêtre
- 417 **Interest of QuantIFERON®-TB (QT) Gold test (Cellestis) in patients with positive Tuberculin Skin Test (TST) in etiologic and therapeutic work-up in uveitis**  
DE MONCHY I, GENDRON G, KASWIN G, POGORZALEK N, OFFRET H, LABETOULLE M-Kremlin-Bicêtre
- 418 **Ocular hypertension and uveitis: about 103 cases of uveitis**  
POGORZALEK N, DE MONCHY I, GENDRON G, KASWIN G, LABBE A, OFFRET H, LABETOULLE M-Kremlin-Bicêtre, Paris

## Retina/Vitreous

Moderators: Constantin POURNARAS, Charles RIVA

- 419 **Outcome following ranibizumab therapy for neovascular age related macular degeneration in patients with poor, intermediate and good vision**  
ADEPEGBA O, JYOTHI S, GUPTA B, SIVAPRASAD S-London
- 420 **Wet AMD treatment with ranibizumab - structural and functional changes during treatment**  
RADECKA L, LAGANOVSKA G-Riga
- 421 **Anti-VEGF therapy and influence of vitreomacular traction in wet AMD**  
CORTES MORA N, LOPEZ GALVEZ MI, MANZANAS LEAL L, RODRIGUEZ DE LA RUA FRANCH E, GIRALDO ARGUELLO A-Valladolid
- 422 **Evaluation and inter-observer analysis of retinography existing clinical classification system to categorize moderate retinopathies**  
SANchez RAMOS C, WASFI M, BONNIN-ARIAS C, VINAS-PENA M, FORLAN A, MOLINA-GOMEZ M, CHAMORRO E-Madrid
- 423 **Intravitreal bevacizumab for neovascular age-related macular degeneration: twelve months of follow up**  
EL MATRI L, BAKLOUTI K, BOURAOUI R, KORT F, LIMAIE M, BEN YOUSSEF N, LANDOULSI H-Tunis
- 424 **Retinal pigment epithelial tears following administration of intravitreal bevacizumab (3 case reports)**  
KUOLIENE K, CIMBALAS A, AUKSTIKALNIENE M, ASOKLIS R-Vilnius
- 425 **rf Retinal angiomatic proliferation: is intravitreal ranibizumab therapy enough?**  
MARJANOVIC B, GEORGODIS P, MANDAL K, PATRA S-Bristol
- 426 **rf Combined 23-gauge sutureless pars plana vitrectomy (ppV), injection of recombined tissue plasminogen activator (rtPA), expansile gas and bevacizumab treating acute subretinal haemorrhage (SRH) in exudative AMD**  
MAIER M, PERZ C, FEUCHT N, KONRAD J, WINKLER VON MOHRENFELS C, LOHMANN CP-Munich
- 427 **rf Apoptotic activity of intravitreal bevacizumab on rabbit retina**  
TURKCU MF, ALP MN, TURKCU G, KULACOGLU S, KURAL G-Ankara
- 428 **rf Intravitreal bevacizumab as primary local treatment for choroidal neovascularization secondary to uveitis**  
JULIAN K, FARDEAU C, TERRADA C, FRANCAIS C, LEHOANG P, BODAGHI B-Paris
- 429 **rf Photodynamic therapy for symptomatic circumscribed choroidal hemangioma**  
MAYER CF, WACKERNAGEL W, LACKNER EM, SCHNEIDER MR, HAAS A, WEGER M, LANGMANN G-Graz
- 430 **Comparison of corneal thickness, anterior segment depth and pupil diameter between patients with neovascular age-related macular degeneration and controls**  
PAHOR D, KNEZ N, SISKO K-Maribor
- 431 **Repeatability in the measurement of macular pigment optical density using the Metropsis Test**  
PEREZ CARRASCO MJ, BARRIO AR, PALOMO C, PUELL MC-Madrid
- 432 **Comparison of macular pigment optical density (MPOD) between a northern European and a Mediterranean population**  
TSIKA C, MAKRIDAKI M, PLAINIS S, TSILIMBARIS M, PALLIKARIS IG-Heraklion, Manchester
- 433 **Verteporfin encapsulated in cationic liposomes as an alternative drug for PDT**  
RANJBAR M, MARTIN G, AGOSTINI HT-Freiburg
- 434 **Effects of photodynamic therapy on retinal vessels in the mouse model of laser-induced choroidal neovascularization**  
EVERS C, RANJBAR M, GROSS NJ, MARTIN G, AGOSTINI HT-Freiburg im Breisgau
- 435 **Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: one year follow-up**  
KORT F, BOURAOUI R, CHEBIL A, CHAKER N, CHAABOUNI A, MGHAIEF F, EL MATRI L-Tunis
- 436 **Macular edema and neovascularization in a case of Stargardt macular dystrophy**  
KARAMPATAKIS V, VOUTAS S, LAKE S, KORDALI P-Thessaloniki

- 437 Some questions of immune response to retinal S-antigen and development of myopia's complications  
LAZUK AV, SLEPOVA OS-Tula, Moscow
- 438 Treatment of neovascularization myopic with ranibizumab: 18-month results  
EGEA ESTOPINAN MC, TORRON FERNANDEZ-BLANCO C, GUERRI MONCLUS N, PRIETO CALVO E, FERRER NOVELLA E, RUIZ MORENO O, PABLO LE-Zaragoza
- 439 Bevacizumab and ranibizumab treatments for neovascularization from causes other than age-related macular degeneration  
AZIZ S, BANERJEE S-Leicester
- 440 Comparison of spectral-domain cirrus optical coherence tomography (OCT) and time-domain Stratus OCT for the evaluation of macular and peripapillary retinal nerve fiber layer thickness in patients with diabetes type 2  
GIL ARRIBAS L, GARCIA MARTIN E, IDOPE M, FUERTES I, PINILLA I-Zaragoza
- 441 Differences in macular thickness studied by time domain optical coherence tomography (OCT) and spectral domain OCT in healthy subjects  
IDOPE M, GIL ARRIBAS L, PINILLA I, GARCIA MARTIN E, FUERTES LAZARO M-Zaragoza
- 442 Comparison of Spectralis Fourier-domain optical coherence tomography (OCT) and time-domain Stratus OCT for the evaluation of macular thickness in patients with diabetes mellitus type 2  
GIL ARRIBAS L, IDOPE M, GARCIA MARTIN E, PINILLA I, FUERTES I-Zaragoza
- 443 Comparison of the peripapillary retinal nerve fiber layer thickness in healthy subjects measured by spectral-domain Cirrus optical coherence tomography and time-domain Stratus optical coherence tomography  
FUERTES I, PINILLA I, GARCIA MARTIN E, GIL ARRIBAS L, IDOPE M, CALVO PEREZ P-Zaragoza
- 444 Repeatability of retinal nerve fiber layer and macular thickness measurements using Cirrus Fourier-domain optical coherence  
GARCIA MARTIN E, PINILLA I, IDOPE M, GIL ARRIBAS L, FUERTES I, PUEYO V-Zaragoza
- 445 Comparison of spectral-domain Cirrus optical coherence tomography and time-domain Stratus optical coherence tomography for the evaluation of macular thickness in healthy subjects  
FUERTES I, PINILLA I, GARCIA MARTIN E, IDOPE M, GIL ARRIBAS L-Zaragoza
- 446 Retinal nerve fiber layer and macular thickness measured with Cirrus and Spectralis Fourier-domain optical coherence tomographies: comparative study in healthy eyes  
PINILLA I, GARCIA MARTIN E, IDOPE M, GIL ARRIBAS L, FUERTES MI, FERRERAS A-Zaragoza
- 447 Clinically useful wide-field high-resolution retinal imaging optics with a dual-conjugate adaptive instrument  
SJÖSTRAND J, KNUTSSON P, POPOVIC Z, THAUNG J-Gothenburg
- 448 Optical coherence tomography and biomicroscopical analysis in macular holes  
FRUSCHELLI M, MOTOLESE I, MOTOLESE PA, FREZZOTTI P, MOTOLESE E-Siena, Grosseto
- 449 Local and genetical determinants of vascular endothelial growth factor in vision threatening proliferative diabetic retinopathy  
GLOBOCNIK PETROVIC M, HAWLINA M, KOSNIK M, KOROSEC P, PETROVIC D-Ljubljana, Golnik
- 450 Intraoperative combination of triamcinolone acetonide – bevacizumab (Kenacort-Avastin) in diabetic macular edema  
ELEFTHERIADOU M, FRAGISKOU S, PANTELEONTIDIS V, PAPADAKI T, TSILIMBARIS M, PALLIKARIS IG-Heraklion
- 451 Visual function vs quality of life assessment in patients with laser-treated diabetic macular oedema  
PEARCE L, SIVAPRASAD S, CHONG V-London, Oxford
- 452 Use of the contrast sensibility in the diagnosis of diabetic retinopathy and diabetic macular edema  
IBANEZ J, VALYI Z, PEREZ GARCIA D, PEIRO C, CRISTOBAL JA, FAURE E, SAINZ A-Zaragoza
- 453 Use of retinal photography in the diagnosis of clinically significant macular edema (CSME)  
IBANEZ J, PEREZ GARCIA D, VALYI Z, MATEO OROBIA AJ, CRISTOBAL JA, FAURE E, SAINZ A-Zaragoza
- 454 Ocular and systemic endothelial function in the offspring of diabetics: a pilot study  
PATEL S, GHERGHEL D, HEITMAR R, BENAVENTE-PEREZ A, QIN L, MCINTYRE D, BALANOS G, GIBSON J-Birmingham, New York
- 455 Long-term result of intravitreal steroid for macular oedema:  
*rf* 2- to 5-year follow-up of 92 eyes  
ZAIDI F, ANSARI E-Maidstone
- 456 The relationship between retinal hemodynamics and systemic markers of endothelial function and inflammation in type 2 diabetes  
HUDSON C, KHUU LA, PALKA E, FLANAGAN JG, WONG T, LAM WC, MARKOWITZ SN, BRENT M, MANDELCORN M, DEVENYI RG-Toronto
- 457 Assessment of retinal arteriolar hemodynamics in patients pre- and post-cataract extraction  
*rf* HUDSON C, AZIZI B, WAN J, WONG T, SINGER S-Toronto, Waterloo
- 458 Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy  
MUQIT MMK, GHANCHI FD, WAKELY L, HENSON DB, STANGA PE-Manchester, Bradford
- 459 Efficacy after intravitreal bevacizumab and triamcinolone injection in BRVO patients  
CHOI M, LEW Y-Seoul
- 460 Bilateral central serous chorioretinopathy in a patient with focal segmental glomerulosclerosis  
PRIETO CALVO E, EGEA ESTOPINAN MC, GUERRI MONCLUS N, RUIZ MORENO O-Zaragoza
- 461 Internal limiting membrane surrounding idiopathic stage 4 macular hole contains bundles of actin microfilaments  
MENDRINOS E, TSILIMBARIS M, TSOKA P, BOCHATON-PIALLAT ML, GILODI N, POURNARAS CJ-Geneva, Heraklion
- 462 Mechanics of a macular hole: formation and surgical closure  
PEDDADA R, WEINBERG D-Casper, WY, Milwaukee, WI
- 463 Long-term visual prognosis in necrotising herpetic retinitis  
COSTANTINI E, DUCOS DE LAHITTE G, TRAN T, CASSOUX N, FARDEAU C, TERRADA C, AKNIN C, ROZENBERG F, LEHOANG P, BODAGHI B-Paris
- 464 Vitreous haemorrhage and retinal vasculitis as manifestations of cat-scratch disease  
DORE S, CONTINI E, CARTA F, PINNA A-Sassari
- 465 Syphilis, return of an old disease?  
KRAUT A, VIDOVIC VALENTINCIC N-Ljubljana



Why you need to be reading



# Acta Ophthalmologica

- **Impact** – our impact factor continues to increase and now stands at **2.138\***, placing us amongst the most highly cited ophthalmology journals
- **Coverage that's relevant to you** – encompassing all aspects of the anatomy, function and diseases of the eye
- **Official publication** of EVER and all five Nordic Ophthalmological Societies

**MEMBERS OF EVER RECEIVE FREE ONLINE  
ACCESS TO ACTA OPHTHALMOLOGICA**

\*2008 Journal Citation Reports, Thomson Reuters

To make sure *Acta Ophthalmologica* is part of your collection,  
or to submit an article visit: [www.actaophthalmologica.com](http://www.actaophthalmologica.com)



## FOR SIGHT:

The Future of Eye and Vision Research

May 2–6 • Fort Lauderdale, Florida

Abstract submission: October 15–December 4, 2009

[www.arvo.org/am](http://www.arvo.org/am)









**KEYNOTE LECTURES**

- DUA H > Wednesday, 17:20  
 GLOOR B > Wednesday, 18:05  
 JONAS J > Wednesday, 18:25  
 GILMORE M > Thursday, 10:00  
 OHNO-MATSUI K > Friday, 10:00  
 GRAVES A > Friday, 11:00  
 SMITH J > Friday, 15:30  
 COUPLAND S > Saturday, 10:00

- BRECELJ J: 2263  
 BREMOND-GIGNAC D: 273, 2362  
 BRISCOE D: 4368  
 BRON AJ: 2332  
 BRON AM: 1255, 1346, 2254, 3453, 4245  
 BUCHT C: 3332  
 BUSIN M: 3432  
 BUSUTTIL A: 4428  
 CACHAFEIRO M: 4336  
 CALIENNO R: 3133  
 CALVO PEREZ P: 233, 2252  
 CANADAS SUAREZ P: 315, 331, 2272  
 CARTER JG: 2246  
 CASSOUX N: 4163  
 CELLINI M: 222, 2453  
 CHAI SM: 251  
 CHATEAU N: 2434, 4316  
 CHEBIL A: 250  
 CHIAMBARETTA F: 2364  
 CHIQUET C: 1342, 4111, 4412  
 CHODOSH J: 4222  
 CHOI M: 459  
 CHONG V: 2343  
 CHUPROV A: 3346  
 CIANCAGLINI M: 3236  
 CIOLINO J: 4426  
 COCHENER B: 1256, 2432, 4242  
 COLLIARDO P: 4325  
 COMBEY-DE LAMBERT A: 3344  
 CORTES MORA N: 421  
 COSTANTINI E: 463  
 COUPLAND SE: 3264, 4367  
 CREUZOT C: 1321, 1341, 2474, 3312, 4114, 4244  
 CURCIO C: 2233  
 DA CRUZ L: 2131  
 DAMATO B: 1232, 1362, 4165, 4262, 4365  
 DASTIRIDOU AI: 226, 2457  
 DE BROUWERE D: 3243  
 DE LA CRUZ J: 330, 2172  
 DE LA PAZ MF: 303, 2224, 3137, 4122, 4224  
 DELGADO E: 2123  
 DEMESTICHA A: 319  
 DE MONCHY I: 417  
 DENDALE R: 4261  
 DESJARDINS L: 1252, 1363, 4161, 4263, 4362  
 DE SMET M: 1214, 1218, 121c, 1345, 2112, 3213, 4115, 4155  
 DE SOUZA-RAMALHO P: 2121  
 DE WIT DW: 302, 3136  
 DICK AD: 2324, 3466  
 DJOJOSUBROTO M: 2234  
 DOBNER B: 4353  
 DODI PL: 327, 410  
 DOHLMAN CH: 313, 2176, 4123  
 DOMINIK A: 3333  
 DOPIERALA J: 3263  
 DORE S: 464  
 DOVRAT A: 3341  
 DUA HS: 1322, 2477, 3234  
 EDWARDS AO: 2344  
 EGEA ESTOPINAN MC: 353, 438  
 EGGENBERGER E: 3162, 3164  
 EHLKEN C: 2413  
 ELEFTHERIADOU M: 450, 2211  
 ELMALEH V: 4131  
 EL MATRI L: 423  
 EVERE C: 434  
 FAGERHOLM P: 4421  
 FALCINELLI G: 4226  
 FALCINELLI GC: 4125  
 FALSINI B: 4414  
 FERNANDES R: 2122, 3446  
 FERRERAS A: 232, 234  
 FRANCES-MUNOZ E: 408, 409  
 FRANCO S: 318, 322  
 FRUSCHELLI M: 448, 2215  
 FUCHSLUGER T: 3465  
 FUERTES I: 443, 445  
 FUKUDA M: 4322  
 GAJECKA M: 2244  
 GALGAUSKAS S: 202  
 GALLAR J: 2225  
 GALLEGO-PINAZO R: 246, 339, 2411  
 GARAS A: 2253  
 GARCIA MARTIN E: 344, 444  
 GARHOFER G: 2351  
 GEORGI T: 362  
 GERDIN AK: 4141  
 GHERGHEL D: 2353  
 GIANNAKOPOULOU T: 361  
 GICQUEL JJ: 1326, 2433, 3235  
 GIL ARRIBAS L: 440, 442  
 GINIS H: 3126, 3242  
 GLOBOCNIK-PETROVIC M: 449  
 GOMAA A: 4327, 4427  
 GOMES N: 2124  
 GONZALEZ C: 3311  
 GRABNER G: 4221, 4228  
 GRACNER T: 221, 2256  
 GRACZYNSKI M: 1233  
 GRANGE JD: 4366  
 GRAVES A: 3251  
 GRAW J: 2241  
 GRZYBOWSKI A: 1232  
 GUERRI MONCLUS N: 230  
 GUGLETA K: 2352  
 HALFED FURTADO DE MENDONCA R: 241, 366, 2146, 3322  
 HAMEL C: 3323  
 HAMMER M: 2465  
 HARDARSON SH: 2461  
 HART PM: 247, 248, 2444  
 HAWLINA M: 1254, 2471, 3224  
 HAY A: 407  
 HEEGAARD S: 3261  
 HEIMANN H: 4167  
 HELLGREN K: 2161  
 HELLSTRÖM A: 2165  
 HERBORT CP: 121b, 4153, 4451, 4455  
 HERWIG MC: 351  
 HILLE K: 4423  
 HOLAN V: 205  
 HOLDER GE: 3225, 3424  
 HORNE M: 2113  
 HUDSON C: 456, 457, 4213, 4215, 4216  
 HUGHES E: 4328  
 HULL C: 4424  
 IBANEZ J: 452, 453  
 IDOPE M: 236, 441  
 IOMDINA E: 2154  
 IVASTINOVIC D: 3112  
 JACOBSON L: 2164  
 JAKOB E: 406  
 JANSONIUS N: 2251  
 JARDELEZA MS: 310, 2173  
 JONAS JB: 252, 1344, 2443, 4112  
 JONUSCHEIT S: 363  
 JOYCE N: 3435  
 JULIAN K: 428, 2417  
 JÜNEMANN A: 2242  
 KAARNIRANTA K: 215, 4333  
 KABANAROU SA: 3411  
 KACHANOV A: 334, 335, 3331  
 KADOR PF: 3142, 3445  
 KANG K: 261  
 KARAMPATAKIS V: 305, 413, 436, 3139  
 KARLOVA E: 208  
 KARLSSON JO: 3342  
 KARYOTAKIS NG: 228  
 KASWIN G: 323  
 KATSIMPRIS J: 3413  
 KAWASAKI A: 3163  
 KAYA S: 270  
 KAZARYAN AA: 237  
 KERNT M: 337  
 KESTELYN P: 1325  
 KHAIALLAH M: 1213, 4154, 4452  
 KHAWAJA A: 2473  
 KHAYI H: 266  
 KIEKENS S: 4132  
 KIM S: 235  
 KINOSHITA SS: 4323  
 KIRK A: 346  
 KIVELÄ T: 1231, 1233, 1361, 2371, 3362, 4266, 4364  
 KLAVER C: 2345  
 KLINTWORTH GK: 3363  
 KNOP E: 2232, 2331  
 KNOP N: 2333  
 KOCH P: 2265, 3463  
 KONSTANTAKOPOULOU E: 3125  
 KONTADAKIS GA: 308, 2274, 3337  
 KORT F: 435  
 KOSINA-HAGYO K: 321  
 KOTECHA A: 3352  
 KOTLIAR KE: 2151, 2221  
 KOURENTIS C: 3412  
 KOWALSKI RP: 401, 4252, 4254, 4356  
 KRAUT A: 465  
 KRIAUCIUNIENE L: 358  
 KRONSCHLÄGER M: 338  
 KRUKONYTE R: 203  
 KUDRYAVTSEVA Y: 3345  
 KUOLIENE K: 424  
 KUSNYERIK A: 201  
 LABBE A: 2313  
 LABETOULLE M: 416, 1323  
 LACHAPELLE P: 3223  
 LA COUR M: 2463  
 LANZL IM: 2422  
 LARKIN F: 3436  
 LASTA M: 2423  
 LAUDE A: 3315  
 LAZUK AV: 437  
 LENASSI E: 2144

- LEROUY BP: 3422  
 LEVEZIEL N: 4313  
 LIANG F: 342, 2267  
 LIBONDI T: 245, 2447, 3313  
 LIM L: 253  
 LIU C: 4121  
 LOEFFLER KU: 4361  
 LÖFGREN S: 3442  
 LOPEZ-GIL N: 2435  
 LOTERY AJ: 2341  
 LOU M: 3141, 3443  
 MACKENSEN F: 4454  
 MACKEY D: 2346  
 MAIER M: 426, 3113, 3317  
 MAILLON C: 4315  
 MAKHOUL D: 4135  
 MAKHOUL M: 402, 4357  
 MANGIORIS G: 333  
 MANKOWSKI W: 3321  
 MANTOVANI A: 4456  
 MARANGONI D: 4416  
 MARJANOVIC B: 425, 3316  
 MARQUES-NEVES C: 223, 224, 2454, 2455  
 MARTIN L: 220, 2255  
 MASSAMBA N: 4314  
 MATTER JM: 2141  
 MAYER CF: 429, 2418  
 MCNAUGHT A: 2466  
 MENCUCCI R: 411, 2436  
 MENDRINOS E: 267, 461  
 MICHAEL R: 316, 3245  
 MIDELFART A: 2261  
 MIDENA E: 1364  
 MIHELCIC M: 3324  
 MILANO G: 231  
 MILAZZO S: 2363  
 MILKA M: 309, 2275, 3338  
 MØLLER HU: 3361  
 MÖNSTAM E: 336  
 MONTAVON P: 218  
 MONTERO MORENO JA: 403, 2412, 4358  
 MORTEMOUSQUE B: 2365  
 MULFORD C: 4143  
 MUQIT MMK: 458, 4217  
 MURAINÉ M: 3434  
 NEPP J: 304, 3138, 3334  
 NERI P: 1219, 121a, 4156  
 NICHOLLS S: 2271  
 NISCHAL KK: 2361  
 NOCZEZ Y: 340, 349, 3267  
 NOVAK ANDREJCIC K: 350  
 NOWINSKA A: 314, 2243, 2277  
 NUBILE M: 3232  
 NUNES S: 4212  
 OBROSOVA IG: 3143  
 OLAFSDOTTIR OB: 2464  
 OLESEN H: 2276  
 OLOFSSON EM: 3444  
 O'NEILL-BIBA M: 3124  
 ORGUL S: 4415  
 OSBORNE NN: 2322  
 PADRICK T: 3326  
 PAHOR D: 430  
 PAJTLER A: 254  
 PALADINI I: 3134  
 PALLIKARIS IG: 2153  
 PAPPAS G: 3414  
 PAQUES M: 2311  
 PARROZZANI R: 4164  
 PATEL S: 454  
 PEARCE L: 451  
 PEDDADA R: 462  
 PEDROSA DOMELLOF F: 2231  
 PEDROTTI E: 3231  
 PE'ER J: 4363  
 PEMB B: 2424  
 PENTARI I: 307, 3336  
 PEREZ VS: 4324  
 PEREZ CARRASCO MJ: 431  
 PEREZ GARCIA D: 325, 354  
 PERLMAN I: 3222  
 PESCE G: 328  
 PETROVSKI G: 4332  
 PHILIPPAKI E: 360  
 PILLUNAT L: 2451  
 PINELLO L: 256  
 PINILLA I: 217, 446  
 PINNA A: 249  
 PISELLA PJ: 2431  
 PLANT G: 1231  
 PLEYER U: 1211, 3464, 4253  
 POCOBELLI A: 2273  
 POGORZALEK N: 418  
 POPOSKI V: 3314  
 POURNARAS CJ: 1251, 1343, 2462, 4113, 4413  
 PRASANNA G: 2323  
 PRAUSE JU: 1366, 2472  
 PRIETO CALVO E: 263, 460  
 PROSDOCIMO G: 4227  
 PUELL MC: 356  
 PUK O: 4142  
 RABENSTEINER DF: 207  
 RADECKA L: 420  
 RAMIREZ AI: 211  
 RAMIREZ JM: 213  
 RANJBAR M: 433  
 RAUSCHER F: 359, 3123  
 REHAK M: 2414  
 REITSAMER HA: 244, 2421, 2446  
 RESENDE AP: 2125  
 RITTER T: 3462  
 RIVA CE: 2375  
 ROCHA DE SOUSA A: 265  
 ROMANOWSKI EG: 4255  
 ROUX M: 4144  
 ROZEMA J: 3244, 4133  
 RUNGE CW: 268  
 RUSSO A: 4166  
 SANCHEZ RAMOS C: 357, 422  
 SAW SM: 3325  
 SAYEGH RR: 320  
 SCHALENBOURG A: 4168  
 SCHIRRA F: 2334  
 SCHMETTERER L: 2155, 2321, 2354, 4411  
 SCHMIDL D: 2452  
 SCHOLL HPN: 2342  
 SCHOLLMAYER P: 415  
 SEGUIL CRESPO MM: 364, 365  
 SEREGARD S: 1365, 2374  
 SERRA U: 4354  
 SETHI S: 243, 352, 2148, 3262  
 SETROUK E: 2415  
 SHAMSHINOVA AM: 369  
 SHEN T: 2171  
 SIMON E: 272  
 SJÖSTRAND J: 447  
 SKOTTMAN H: 2132  
 SMITH ND: 3353  
 SNEAD M: 3211  
 SÖDERBERG PG: 3441, 4311  
 SPILEERS W: 2373, 3421  
 STALMANS I: 2156, 3151, 3451  
 STANNARD C: 4264  
 STANOJLOVIC S: 329  
 STEFANIOTOU M: 3416  
 STEHOUWER M: 2213  
 STEVENS AM: 3354  
 STOIBER J: 4126  
 STOJANOVIC N: 229, 255  
 STRASSER T: 370  
 STRATOS A: 317  
 STROHMAIER C: 269  
 STRUBLE CB: 259, 2426  
 STUNF S: 412  
 SURIANO M: 3155  
 TALONI M: 4425  
 TASSIGNON MJ: 2372  
 TEKAVCIC POMPE M: 3121  
 TEMPRANO J: 4225, 4326  
 TENGKU KAMALDEN TA: 214  
 THERMOS K: 2325  
 THURET G: 3433  
 TODANI A: 225, 2456  
 TRANOS P: 3415  
 TRIVINO A: 212  
 TSIKA C: 432, 2223  
 TSILIMBARIS M: 4334  
 TSOKA P: 4331  
 TUGAL-TUTKUN I: 4151  
 TURKCU MF: 427, 2416  
 URTTI A: 2133  
 VALYI Z: 324, 326  
 VAN AKEN E: 3215  
 VAN BERGEN T: 2442, 4134  
 VAN CALSTER J: 4231  
 VAN DEN BERG TJTP: 3241  
 VAN DE VEIRE S: 2441, 4232  
 VANDEWALLE E: 3152, 4233  
 VAN GINDERDEUREN R: 3153, 4162  
 VAN MARLE G: 209  
 VARSANYI B: 368  
 VASSILEVA P: 2476  
 VELIKAY-PAREL M: 3115  
 VERBRAAK FD: 2111, 2212  
 VERONESE RODRIGUES ML: 239, 2445  
 VIDOVIC VALENTINCIC N: 414  
 VIIRI J: 216, 271  
 VILLAFRUELA I: 343, 345  
 VOIGT M: 1253  
 VON HOLSTEIN SL: 3265  
 VORONKOVA E: 2458  
 WACKERNAGEL W: 348, 3266  
 WEGENER A: 3144, 4241  
 WEGER M: 2143  
 WILLERMAIN F: 1212, 2235  
 WOOD T: 3131

## Thank you sponsors

EVER wishes everyone of its past and present sponsors good future for the comming years and thanks especially the following companies, many of which are our long-term supporters, for their generous sponsorship. Thanks to their support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

### Main sponsor



### SIS sponsors



### CIS sponsors



**Exhibitors**



**Welcome reception**



**Media sponsors**

Ophthalmology Times

## This programme book is organised chronologically

Four digit numbers refer to oral presentations

X X X X  
Day | Timeslot | Hall | Order in session

Three digit numbers refer to posters

X X X  
Day | Order in the postersession

## The sessions are colour-coded

Special Interest Symposium (SIS)

Keynote Lecture

Workshop

Free Papers (FP)

General Assembly & Business Meeting

Poster Session

Joint Meeting

Course

Social

Commercial Interest Symposium (CIS)

**FP** = Free Paper session

**SIS** = Special Interest Symposium

**CIS** = Commercial Interest Symposium

= EVER travel grant recipient

= EVER listed countries travel grant recipient

= Alta Eficacia Tecnología SL, Spain, travel grant recipient

**rf** = Rapid Fire presentation

## Scientific sections

**ACB** = Anatomy/Cell Biology

**COS** = Cornea/Ocular Surface

**G** = Glaucoma

**IM** = Immunology/Microbiology

**IC** = Lens and Cataract

**MBGE** = Molecular Biology/Genetics/ Epidemiology

**NSPH** = Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/History of Ophthalmology

**PBP** = Physiology/Biochemistry/Pharmacology

**PO** = Pathology/Oncology

**RV** = Retina/Vitreous

**VEP** = Vision Sciences/Electrophysiology/Physiological Optics

# EVER 2010

October 6-9, 2010

Crete [www.ever.be](http://www.ever.be)



## Call for Course and SIS 2010

Proposals for courses and SIS are welcome online from November 20, 2009 on.  
The deadline for submission of outlines is January 20, 2010 through the EVER website.  
Submissions must be discussed with the Section Programme Secretary.

	<b>Europa A</b>	<b>Europa B</b>	<b>Emerald I</b>	<b>Emerald II</b>	<b>Mediterranea I</b>	<b>Adria</b>	<b>Daphnia</b>
<b>WEDNESDAY</b>							
12:00-14:15	W: Course 1: immune modulation in ocular disease U PLEYER, CP HERBORT, B BODAGHI, P NERI	PO: Course 3: Well versed in statistics TKIVELA, B DAMATO	RV: Course 4: EBO: Clinical analysis > final diagnosis C CREUZOT	RV: Course 6: Retinal detachment C CREUZOT, C POURNARAS	RV: Course 7: EBO course: Ophthalmic Oncology L DESJARDINS		
14:30-16:45	COS: Course 5: Corneal infections disease JJ GICQUEL, HS DUA						
17:00-17:15	Welcome by the President EVER 2009 • Charles RIVA						
17:20-18:00	EVER lecture • Corneal surface regeneration: epithelial sheets to epithelial crypts • Harminder DUA						
18:05-18:20	European Ophthalmologic Heritage Lecture • Hans Goldmann (1899 – 1991) • Balder GLOOR						
18:25-19:00	EVER Acta Lecture • From intravitreal cell-enclosed drug therapy to low-[brain]-pressure-glaucoma • Jost JONAS						
19:00-20:00	Opening concert						
20:00-21:30	EVER Welcome reception with musical entertainment lobby S. Bernardin						
<b>THURSDAY</b>							
08:15-09:45	Eurefira: Development OCT technology and its applications • R BENNARDS	PBP: Apoptosis and angiogenesis in retinal neurovascular degeneration • P DESOUZA, R AMALHO	ACB: New concepts tissue reconstruction in RPE-H USTYLO, K KAARNIRANTA	MGE: Free papers B LEROY, A CHURCHILL	G: Ocular Rigidity: Biomechanical aspects and clinical applications • K KOHLER	NSPH: Visual function following prematurity and/or very low birth weight • L MARTIN	COS: KPro cornea • C LIU
10:00-10:45	<b>Keynote Lecture 1</b> • Pathogen interactions in the pathogenesis of Endophthalmitis • Michael GILMORE:	PBF: Physiology-Biochemistry-Pharmacology 1 P BISHOP, T SCHMETTERER	ACB: Ocular anatomy and cell biology N KNOP, V ARSENEVIC	MGE: Genes and markers in AMD M VOTRUBA, A EDWARDS	G: Monitoring glaucoma patients: visual field and imaging • ZEYEN, J. JONAS	NSPH: Neuro-ophthalmology and Immunology F. BORRIAT, P. NERI	CONCORDIA: Designing effective courses M HAWLINA, W SPILERS, C RIVA
11:00-12:30	RV: Visualization techniques of the retina F VERBRAAK, C ARNDT	PBP: Physiology-Biochemistry-Pharmacology 1 P BISHOP, T SCHMETTERER	MGE: Genotypes and phenotypes J GRAN, M GAJECKA	MGE: Free Papers 3 SM SW, M VOTRUBA	G: Blood flow in glaucoma - new horizons S ORGUL	NSPH: Management in pediatric ophthalmology D BREMOND-GIGNAC, S MILAZZO	Europa A
12:35-13:35	Lunchtime CIS • Théo: Ocular surfaces, what's new in 2009?	RV: In vivo imaging of cellular dynamics in the eye • M PAQUES	PBP: Nitric oxide in the healthy and unhealthy eye • T SCHMETTERER, N OSBORNE	ACB: The Melibomian gland - revisited E KNOP, K KNOP, A BRON	G: Monitoring glaucoma patients: visual field and imaging • ZEYEN, J. JONAS	NSPH: Management in pediatric ophthalmology D BREMOND-GIGNAC, S MILAZZO	Europa A
13:45-15:15	Keynote Lecture 2 • Common or individual molecular mechanisms underlying different forms of retinal degeneration • Valerie MARIGO PhD	PBP: Physiology-Biochemistry-Pharmacology 2 N OSBORNE, H REITSAMER	COS: wavefront aberrometry and adaptive optics JJ GICQUEL, P J PISIELLA	MGE: Free Papers 3 SM SW, M VOTRUBA	G: Pressure and blood flow in glaucoma C MARQUES-NEVES, X-M STEVENS	NSPH: Refraction in health and disease E STEFANSSON, C POURNIKARAS	Europa C
15:30-16:10	Poster Session 1 • Anatomy/Cell Biology - Glaucoma - Molecular Biology/Cytogenetics/Epidemiology - Physiology/Biochemistry/Pharmacology						
16:15-17:25	Poster Session 1 • Anatomy/Cell Biology - Glaucoma - Molecular Biology/Cytogenetics/Epidemiology - Physiology/Biochemistry/Pharmacology	RV: Alternative applications for anti-VEGF therapy and PDT • H AGOSTINI, JJ DELAEY	PBP: Physiology-Biochemistry-Pharmacology 2 N OSBORNE, H REITSAMER	MGE: Free Papers 3 SM SW, M VOTRUBA	G: Retinal oxygenation in health and disease E STEFANSSON, C POURNIKARAS	NSPH: Refraction in health and disease E STEFANSSON, C POURNIKARAS	Europa C
17:30-19:00							
19:00-20:00	Evening CIS • MSD: Ocular blood flow and glaucoma – an update						
<b>FRIDAY</b>							
08:15-09:45	RV: Vitreoretinal surgery from past to future P KOCH, E VAN AKEN	VEP: Colour vision B LEROY, W SPILERS	COS: Ocular surface and dry eye P J PISIELLA, P KESTELYN	LC: Didabetic cataract mechanisms and management • JOBROSOVA, P KADOR	G: Glaucoma surgery J STALMANS, A BRON	NSPH: Jumping, Jigging and shaking eyes A KAWASAKI, F BORRIAT	Europa A
10:00-10:45	<b>Keynote Lecture 2</b> • Age-related macular degeneration: an Alzheimer's disease in the eye? • Kyoko OHNO-MATSUI	VEP: ISCEV Session C BARBER, P LACHAPELLE	COS: Anterior Segment Imaging JJ GICQUEL, M NUBLE	LC: Straylight in the human eye - Small versus large angle domain • R MICHAEL H GINS	Women in ophthalmology: From bench to boardroom • A GRAVES	PO: Pathology-Oncology free papers S HECA-AARD, T KRELA	Europa A
11:00-12:30	RV: Novelties in basic research in the vitreous E VAN AKEN, MD DE Smet						
12:35-13:35	<b>Business Meetings of the Scientific Sections • Sandwiches and Refreshments</b>	RV	VEP / PBP	COS / ACB	LC / MBGE	G / IM	BPO / NSHP
13:45-15:15	RV: Treatment of age-related macular degeneration • C CREUZOT, J DE LAEY	VEP: Electrophysiology G HOLDER, J BARBUR	COS: Refractive surgery and anterior segment imaging cornea • G THURET, B COCHENER	LC: Lens J-O KARLSSON, A WEGENER	G: Glaucoma and disability A-M STEVENS, T ZEPEN	PO: The IC3D classification of corneal dystrophies and beyond • T KIVELA, HU MÖLLER	Europa A
15:30-16:10	Ophthalmic Research Lecture • Role of the vascular endothelial cell in uveitis • Justine SMITH						
16:15-17:25	Poster Session 2 • Cornea/Ocular Surface - Lens/Cataract - Neuro-Ophthalmology - Pathology/Oncology - Vision Sciences/Electrophysiology/Physiological Optics	RV: Progress in vitro-retinal surgery T XIAO	VEP: Doctor, I see things that aren't there G HOLDER	LC: Oxidation and cataract S DUGREN, M F LOU	G: Trabeculectomy, end of the surgery, beginning of the intervention • I STALMANS, A BRON, T ZEFEN	IM: Gene therapy in ocular inflammation P KOCH, J PLEIER	Europa C
17:30-19:00							
19:00-20:00	Evening CIS • MSD: Ocular blood flow and glaucoma – an update						
<b>SATURDAY</b>							
08:15-09:45	RV: Macular oedema: what is the best treatment? C CREUZOT	KPro 1 session: Design surgical techniques and complications • C DOHMAN, K HILLE P CCILLARDO	FRO: Belgian Fund for Research in Ophthalmology • P KESTELYN, M J TASSIGNON	LC: The vision screen in the European mouse clinics • J GRAW	MI: EVER-SOLE: Progress in quantifying inflammation and monitoring uveitis • P NERI, ITUGAL-TUTKUN	OOG: Protocol 1 S COUPLAND	Europa A
10:00-10:45	<b>Keynote Lecture 3</b> • Unravelling the mysteries of ocular lymphomas • Sach COUPLAND						
11:00-12:30	RV: Diabetic retinopathy at a glance C RIVA	KPro 2 session: Clinical results and indications G GRABNER, G FALCINELLI, J JAQUELLA	FRO: Belgian Fund for Research in Ophthalmology 2 • P KESTELYN, M J TASSIGNON	LC: Microincision cataract surgery (MICS), is smaller better? • A BRON	IM: Anti-infectives from research to clinic R KOWALSKI, E ROMANOWSKI	PO: Radiotherapy in ophthalmic oncology L DESJARDINS, B DAMATO	Europa A
12:35-13:35	Lunchtime CIS • Allegan: Role of inflammation in RVO						
13:45-15:15	RV: New ocular imaging in retinopathies G SOURANE	KPro 3 session J BARRAQUER, G FALCINELLI, J M PAREL	ACB: Cell biology of the retina R BRUEHLE, K KAARNIRANTA	ARVO Session: Finding a US Postdoctoral Fellow Position • S AHERTON	IM: Trends in ocular immunology and microbiology research • P KOCH, R KOWALSKI	OOG: Protocol 2 S COUPLAND	Europa C
15:20-16:30	Poster Session 3 • Immunology/Microbiology - Retina/Vitreous						
16:40-17:40	EVER General Assembly and Prize Giving						
17:45-19:15	RV: Choroidal blood flow in the healthy and diseased eye • B FAISHL, C CHIQUEI	KPro 4 session C LIU, M FUKUDA, M TALONI	IM: How to get your work published ? UPLISTER	MI: Ocular inflammation and infection M KHARALLAH, CP HERBERT	OOG: Business Meeting S COUPLAND	Europa A	Europa A
20:00-23:00	EVER Farewell dinner with musical entertainment						S. Bernardin